Antares Pharma Inc (OTCBB:ANTR) eine AKTIE mit MEGA-Potential - 500 Beiträge pro Seite

[js200]

Antares Pharma`s (OTCBB: ANTR / Amex: AIS as of September 23, 2004) North American Licensee BioSante Pharmaceuticals, Inc. Announces Positive Results of Phase II Study of LibiGel(TM), Topical Testosterone Gel

Antares Pharma Says Study Shows LibiGel(TM) Significantly Increases Sexual Activity in Surgically Menopausal Women Suffering From Female Sexual Dysfunction (FSD)

Wednesday, September 22, 2004 14:55 ET

EXTON, Pa., Sep 22, 2004 /PRNewswire-FirstCall via COMTEX/ -- Antares Pharma, Inc. (OTC Bulletin Board: ANTR)(Amex: AIS effective September 23, 2004), an evolving specialty pharmaceutical company with headquarters in Exton, Pennsylvania, announced today that its topical testosterone gel North American licensee, BioSante Pharmaceuticals, Inc. (Amex: BPA) reported that its placebo-controlled Phase II study showed treatment with LibiGel(TM) significantly increased satisfying sexual events in surgically menopausal women suffering from female sexual dysfunction (FSD).

Today`s announcement follows yesterday`s decision by the Food and Drug Administration to grant Procter & Gamble fast track status for its formulation of Intrinsa(TM), an investigational female testosterone patch, based upon data for its two Phase III trials.

LibiGel(TM) utilizes Antares Pharma`s propriety advanced transdermal delivery (ATD(TM)) gel technology designed to allow delivery of hormones and other products across the skin. The LibiGel(TM) study was a double-blind placebo controlled study in 46 surgically menopausal women. The effective dose of LibiGel(TM) produced testosterone blood levels within the normal physiological range for pre-menopausal women and the safety profile was similar to that of the placebo product.

By incorporating Antares Pharma`s ATD(TM) gel technology, LibiGel(TM) is quickly absorbed through the skin after application on the arms, shoulders or abdomen, evenly delivering testosterone to the bloodstream in a non-invasive and painless manner. Although generally characterized as a male hormone, testosterone is also present in women, and its deficiency has been found to decrease libido (sex drive). Additional information on the study will be presented at the October 30, 2004 Annual Meeting of Sexual Health in Women in Atlanta. Phase III studies are expected to start in early 2005.

Antares Pharma will receive milestone payments at certain stages of development and royalties from end sales of LibiGel(TM) in North America. Additionally, Antares Pharma has rights to the clinical data generated for further licensing of testosterone for the treatment of FSD in other territories, including Europe and Japan.

Jack E. Stover, President and CEO of Antares Pharma, stated, "Credible estimates of the U.S. market for female sexual dysfunction range between $1 billion and $4 billion. We think the market potential in Europe could be as large as the U.S. market, and we also believe the Japanese market will prove to be significant. We are very encouraged by the positive results of BioSante`s clinical study." Mr. Stover added, "Recently, Proctor & Gamble was given fast track status by the FDA for Intrinsa(TM), its transdermal patch containing testosterone for FSD. We believe that this further validates the importance of this unmet medical need. We further believe that gel technology may prove more attractive to patients than transdermal patches."

A study published in the Journal of American Medical Association reported that 43 percent of American women (about 40 million) experience some degree of impaired sexual function. Among the more than 1,400 women surveyed, 32 percent lacked interest in sex and 26 percent could not experience orgasm. The majority of women with FSD are postmenopausal, experiencing FSD due to hormonal changes following menopause, whether natural or surgical.

About Antares Pharma

Antares Pharma is an emerging specialty pharmaceutical company leveraging its experience in drug delivery systems to enhance product performance of established and developing drugs. The Company`s current technology platforms include transdermal (Advanced Transdermal Delivery ATD(TM)) gels, disposable mini-needle injection systems (Vibex(TM)), reusable needle-free injection systems (VISION(R) and Valeo(TM)), and fast-melt oral (Easy Tec(TM)) tablets. The Company currently has active partnering programs with several pharmaceutical and distribution companies for a number of indications and applications, including diabetes, growth disorders, obesity, female sexual dysfunction and other hormone therapy.

Antares Pharma currently distributes its needle-free injector systems in more than 20 countries and markets the same technology for use with human growth hormone through licensees in most major regions of the world. Licensees also market an ibuprofen gel using Antares Pharma`s ATD(TM) technology in several major European countries. In addition, Antares Pharma is undertaking development or is conducting research on several product opportunities that will form the basis of its specialty pharma program. Antares Pharma`s corporate headquarters is in Exton, Pennsylvania, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company`s reports filed with the U.S. Securities and Exchange Commission. Antares Pharma claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

For more information, visit Antares Pharma`s web site at http://www.antarespharma.com. Information included on the Company`s website is not incorporated herein by reference or otherwise.

SOURCE Antares Pharma, Inc.


CONTACT: Jack E. Stover, President and CEO, [phone], or Lawrence
M. Christian, CFO and Vice President - Finance, [phone], both of
Antares Pharma; or Ira Weingarten or Steve Chizzik, Equity Communications,
[phone], for Antares Pharma

URL: http://www.antarespharma.com
http://www.prnewswire.com



Copyright (C) 2004 PR Newswire. All rights reserved.


-0-


KEYWORD: Pennsylvania
Georgia
INDUSTRY KEYWORD: MTC
HEA
OTC
SUBJECT CODE: SVY
WOM
TDS


STOCK SYMBOLS: [(antr)] [(bpa)] [(ais)]

JS200

[js200]

Der CHART, --------> Ein Traum

Ab 23ten September an der AMEX

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


09/22/2004 (15:01 ET) ANTR: BioSante Announces Positive Phase 2 Results of LibiGel - Knobias



09/22/2004 (14:55 ET) Antares Pharma`s (OTCBB: ANTR / Amex: AIS as of September 23, 2004) North American Licensee BioSante Pharmaceuticals, Inc. Announces Positive Results of Phase II Study of LibiGel(TM), Topical Testosterone Gel - PR Newswire



09/22/2004 (10:11 ET) ANTR: Volume Spike; 9% > 20-adsv, Stock +8.75% - Knobias



09/22/2004 (09:26 ET) ANTR: Filed New Form 8-A12B - Edgar



09/21/2004 (16:22 ET) ANTR: Jumps +8.11%; Vol +79%; Last 90 Min of Trading - Knobias



09/20/2004 (09:35 ET) ANTR: Approved for Listing on AMEX on September 23 - Knobias



09/20/2004 (09:34 ET) Antares Pharma Approved For Listing on the American Stock Exchange - PR Newswire



09/20/2004 (09:33 ET) Antares Pharma Approved For Listing on the American Stock Exchange - PR Newswire



08/31/2004 (13:24 ET) ANTR: Filed New Form SC 13D/A - Edgar



08/31/2004 (08:20 ET) ANTR: Filed New Form 4 - Edgar



08/30/2004 (10:40 ET) ANTR: Volume Spike; 11% > 20-adsv, Stock +4.90% - Knobias



08/30/2004 (09:54 ET) ANTR: Filed New Form 4 - Edgar



08/27/2004 (10:41 ET) ANTR: Volume Spike; 13% > 20-adsv, Stock +4.04% - Knobias



08/27/2004 (07:18 ET) ANTR: Filed New Form 4 - Edgar



08/26/2004 (10:44 ET) ANTR: Filed New Form 4 - Edgar



08/25/2004 (08:19 ET) ANTR: Filed New Form 4 - Edgar



08/24/2004 (08:25 ET) ANTR: Filed New Form 4 - Edgar


JS200

[loss_pro]

Der CHART, --------> Ein Traum

...bis heute

[js200]

@LOSS_PRO

Ja, es kann sein, dass die Aktie abgibt, aber Sie rückt in den Fokus der Grossanleger, wie Fonds usw.

Dann kann Antares nicht viel passieren

Siehe BIOSANTE ( BPA )

Der selbe Chart

JS200

[js200]

Es ist heute zu spät um zuzugreifen

Abwarten heisst es hier, genau so wie bei BPA

200% Kursanstieg innerhalb 2 Monate müssen verdaut werden

JS200

[Hufeland]

Ich habe heute auch ein paar Teile zu 1,73 Dollar gekauft
auf Empfehlung eines WO-Teilnehmer eines anderen Threads.
Er meinte, Das Teil kann bis Ende des Jahres 100% machen.
Da ich kein Trader bin, möchte ich gerne wissen, welche Chancen diese Aktie langfristig hat.

Hufeland

[js200]

@HUFELAND

Sie ist Partner mit BPA-----> Biosante

Beide haben massig zugelegt, fast 200 % die letzten 2 Monate

Ich rechne mit einem Rücksetzer , danach kann es wieder anziehen

Eine Konsolidierung wäre sehr Sinnvol, für beide Aktien

MFG

JS200

[js200]

Hier zum kennen lernen

http://www.antarespharma.com

JS200

[js200]

Needle-free injectors

Antares Pharma pioneered the development of needle-free injectors for personal use, and we have remained a leader as this technology has evolved.

Our flagship product, the Medi-Jector VISION®, is used worldwide for delivering insulin to people with diabetes. We manufacture other devices for our pharmaceutical partners that are branded under various names, including ZomaJet® 2 Vision and SciToJet™, marketed in Europe and Asia for daily injections of human growth hormone (hGH).



Technologies

By building global partnerships, we`re bringing innovative technologies to market faster and more efficiently.

The revolutions taking place in biotechnology, genomics, combinatorial chemistry and high-throughput screening will open the door to an unprecedented flow of potential new products that need effective means of delivery. The opportunities have never been greater for a company like Antares Pharma.

Our research and development efforts already give us a competitive edge. Antares Pharma has invested more than $7 million in research and development since 1998 - more than $2 million of which was funded by third-party-sponsored development programs and licensing fees. We currently hold 22 patents in the injection device sector, with an additional 70 applications pending in the US and other countries. In the drug formulation sector, we hold 5 patents with an additional 30 pending. We are currently developing a number of promising new products.




The Antares Pharma, Inc. website contains information about products and technologies that may or may not be available in any particular country. Information on the website is not to be construed as a promotion or offer to sell any product in any country in which the product is not available.

Information presented in The Antares Pharma website is subject to change and may become out of date over time. It is not intended to be a complete or exhaustive discussion of Antares Pharma products and technologies. The information presented is not a replacement for advice from a health care professional. Consumers should consult their physician or other health care professional for advice on medical matters.


JS200

[js200]

Eli Lilly and Company
Entered into License Agreement in the fields of diabetes and obesity in September 2003

Received milestone payment in December 2003



Ferring Pharmaceuticals
Announced Ferring`s Introduction of Medi-Jector VISION® for Use with Zomacton® Under Their Brand Name, ZomaJet® 2 Vision, in October 2002

Extended Business Relationship for Use of Needle-Free Devices for Delivery of Human Growth Hormone in February 2003



GeneMedix
Formed Collaboration to Link GeneMedix`s Biopharmaceutical Products with Antares Pharma`s Device Technology in March 2003


BioSante Pharmaceuticals
BioSante Initiated Phase II Clinical Trail with Transdermal Testosterone Gel Product that Uses Antares Pharma`s Gel Technology System in October 2002

BioSante Completed Phase II/III Trial for Estradiol Topical Gel Product that Uses Antares Pharma`s Gel Technology System in May 2003

Entered into License Agreement in the fields of diabetes and obesity in September 2003

Received milestone payment in December 2003

BioSante Presented Positive Results from Phase II Trial of LibiGel™, a Topical Testosterone Gel that Utilizes Antares Pharma`s Gel Technology System



Solvay Pharmaceuticals
Entered into License Agreement for Transdermal Gel Technology for Hormone Replacement Therapy in June 1999


MacroMed Incorporated
Signed Collaboration Agreement to Develop Patient-Friendly Depot Delivery Systems in March 2002


Innoject, Inc.
Signed Collaboration Agreement to Incorporate Innoject`s Automatic Retractable Injection Devices into Antares Pharma`s Business Development Portfolio in April 2002


ProSkelia
Signed Development and Option Agreement for New Gel Products




NPMG
Signed License Agreement for New Topical Aesthetic Gel Product

JS200

[js200]

ANTARES PHARMA APPROVED FOR LISTING ON THE AMERICAN STOCK EXCHANGE - August 17, 2004
Antares Pharma, Inc. (OTCBB: ANTR), an evolving specialty pharmaceutical company with headquarters in Exton, Pennsylvania, is pleased to announce that its common stock has been approved, subject to being in compliance with all applicable listing standards on the date trading begins, for listing on the American Stock Exchange (Amex®). Antares Pharma’s common stock is expected to begin trading on Amex® under the symbol “AIS” on September 23, 2004.

ANTARES PHARMA APPOINTS JACK E. STOVER AS CHIEF EXECUTIVE OFFICER (CEO), PRESIDENT AND DIRECTOR -August 17, 2004
Antares Pharma, Inc. (OTCBB: ANTR), an evolving specialty pharmaceutical company with headquarters in Exton, Pennsylvania, today announced the appointment of former President and COO, Jack E. Stover, to the additional roles of Chief Executive Officer and Director. Concurrently, Roger G. Harrison, Ph.D., has resigned effective September 1, 2004, as both Chief Executive Officer and Director to spend more time on personal and other business interests; however, he will remain as a consultant to the Company.

ANTARES PHARMA ANNOUNCES APPOINTMENT OF DR. PAUL K. WOTTON TO ITS BOARD OF DIRECTORS -August 17, 2004
Antares Pharma, Inc. (OTCBB: ANTR), announced today that Dr. Paul K. Wotton was appointed to the Company’s Board of Directors effective August 16, 2004.


ANTARES PHARMA, INC. REPORTS SECOND QUARTER 2004 RESULTS -August 13, 2004
Antares Pharma, Inc. (OTCBB: ANTR) today reported a 24% decrease in total revenue to approximately $691,000 for the second quarter ended June 30, 2004, compared to approximately $908,000 for the same period in 2003, while operating expenses and net operating loss decreased 5% and 3%, respectively.

ANTARES PHARMA ANNOUNCES LAUNCH OF VISION® FOR USE WITH HUMAN GROWTH HORMONE IN JAPAN - August 3, 2004
Antares Pharma, Inc. (OTCBB: ANTR)announced that its Japanese licensee, JCR Pharmaceuticals Co. Ltd. of Ashiya, Japan, has today launched the Twin-Jector® EZ II, a new product that combines Antares Pharma`s VISION® needle-free injection technology with JCR`s human growth hormone.



ANTARES PHARMA ANNOUNCES APPOINTMENT OF JACK E. STOVER AS PRESIDENT AND COO -July 27, 2004
Antares Pharma, Inc. (OTCBB: ANTR) is pleased to announce the appointment of Jack E. Stover to the position of President and Chief Operating Officer (COO). Mr. Stover will be responsible for the overall operations of Antares Pharma`s drug and device businesses presently located in Basel, Switzerland, and Minneapolis, Minnesota, and will report directly to Antares Pharma`s CEO, Dr. Roger G. Harrison.


ANTARES PHARMA BUSINESS DEVELOPMENT HEAD ELECTED TO CHAIR THE ASSOCIATION OF NEEDLE-FREE INJECTION MANUFACTURERS (ANFIM) -July 22, 2004
Antares Pharma, Inc. (Nasdaq: ANTR) announced today that Michael Kasprick, the Company`s Executive Director for Corporate Business Development has been elected Chair of the Association of Needle-Free Injection Manufacturers (ANFIM) organization, effective July 15, 2004.


ANTARES PHARMA PARTNER COMPLETES PHASE II CLINICALTRIALS FOR TESTOSTERONE TRANSDERMAL GEL IN FEMALE SEXUAL DYSFUNCTION -June 29 , 2004
Antares Pharma, Inc. (Nasdaq: ANTR) said today that its U.S. licensee, BioSante Pharmaceuticals, Inc. (AMEX: BPA) completed Phase II clinical trials of LibiGel(TM) (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD). Antares will receive a royalty on U.S. sales of LibiGel by BioSante. In addition, Antares will have the opportunity to independently submit the product for regulatory approval in Europe and Japan - based primarily on clinical data generated by BioSante.


ANTARES PHARMA ANNOUNCES DPT LABORATORIES, LTD. IS PREFERRED SUPPLIER OF TRANSDERMAL GEL TECHNOLOGIES -June 16, 2004
Antares Pharma, Inc. (Nasdaq: ANTR) and DPT Laboratories, Ltd. today announced a letter agreement between the companies whereby DPT will become the preferred development and manufacturing organization for Antares Pharma’s transdermal gel products for clients referred to DPT by Antares Pharma


ANTARES PHARMA CEO DR. ROGER G. HARRISON TO SPEAK AT INDUSTRY CONFERENCE -June 7 , 2004
Antares Pharma, Inc. (Nasdaq: ANTR) announced today that its CEO and President, Dr. Roger G. Harrison, has been invited to be a speaker and panel member at the BIO 2004 meeting in San Francisco, California, scheduled for June 6-9, 2004. BIO 2004 is the world’s leading biotechnology conference and exposition, featuring a slate of internationally renowned speakers and educational seminars and workshops on finance, partnering, research and development, science and policy. More than 20,000 people are expected to attend BIO 2004, including industry leaders, executives, scientists, policymakers and journalists.


ANTARES PHARMA TO PRESENT AT FRIEDMAN BILLINGS RAMSEY 8TH ANNUAL GROWTH INVESTOR CONFERENCE -June 01, 2004
Antares Pharma, Inc. (Nasdaq: ANTR) is scheduled to present at the Friedman Billings Ramsey 8th Annual Growth Investor Conference on Thursday, June 3, 2004, at 11:20 am ET. The conference will be held at the Millennium Broadway Hotel in New York City. The Company will be summarizing the potential applications of its drug delivery platforms and projecting the impact of current business partnerships on its financial plan. In addition, comments will be made in relation to the Company`s transition toward a specialty pharma business.


ANTARES PHARMA CEO DR. ROGER G. HARRISON TO BE FEATURED SPEAKER AT INDUSTRY CONFERENCE -May 20 , 2004
Antares Pharma, Inc. (Nasdaq: ANTR) announced announced today that its CEO and President, Dr. Roger G. Harrison, will be a featured speaker and presenter at the American Association of Pharmaceutical Scientists (AAPS) Workshop on Development, Licensing and Marketing of Injection Drug Delivery Devices for Biotechnology Products. This Workshop will be held on May 20-21, 2004, in Boston, Massachusetts, and Dr. Harrison`s presentation will occur on Friday, May 21, at 10:30 am Eastern.


ANTARES PHARMA, INC. REPORTS FIRST QUARTER 2004 RESULTS -May 14 , 2004
Antares Pharma, Inc. (Nasdaq: ANTR) today reported that when comparing the first quarter 2003 to the first quarter 2004, revenues decreased 20% while gross margins increased from 44.8% to 52.4%, or 7.6 percentage points. In addition, operating expenses decreased 5%, net operating loss improved 5% and other expenses improved 93%. Net loss per share improved 73%, partially due to a decrease in net loss and partially due to a 144% increase in average common shares outstanding. The decrease in total revenue, year to year, resulted primarily from receiving a periodic licensing fee in 2003 as reflected in the following schedule of Reconciliation of Billings to Revenue.



ANTARES PHARMA ANNOUNCES COMPLETION OF STRATEGIC REORGANIZATION MILESTONES -May 10 , 2004
Antares Pharma, Inc. (Nasdaq: ANTR) announced today it has completed its strategic reorganization that began in early 2003 with the outsourcing of production and assembly operations. Throughout 2003 and early 2004, Antares Pharma has focused on decreasing operating costs through reductions in workforce and leased facilities and through improved work processes, reducing average net cash burn from $750,000 to $350,000 per month.



ANTARES PHARMA ANNOUNCES THE ADDITION OF A NEW MEMBER TO ITS BOARD OF DIRECTORS -April 26, 2004
Antares Pharma, Inc. (Nasdaq: ANTR) nnounced today that Rajesh C. Shrotriya, M.D., has joined its Board of Directors effective April 13, 2004. Dr. Shrotriya was appointed to fill a vacant position on the Board.



ANTARES PHARMA PRESENTS TO INVESTMENT COMMUNITY -April 21, 2004
Antares Pharma, Inc. (Nasdaq: ANTR) announced today that it has begun a series of presentations to members of the investment community. The first of these was held in Chicago on April 15, 2004, and similar presentations will follow in Philadelphia, Baltimore and Boston over the next few weeks.



ANTARES PHARMA REPORTS FOURTH QUARTER AND 2003 RESULTS -March 29, 2004
Antares Pharma, Inc. (Nasdaq: ANTR) today released its financial report for the fourth quarter of 2003 and year-end 2003. Dr. Roger G. Harrison, CEO and President of the Company, stated, "Our business continued to make good progress in the fourth quarter of 2003, starting in the third quarter when we announced a license agreement with Eli Lilly and Company for our reusable needle-free technology and the confidence certain investors demonstrated by converting their outstanding debt to equity. Additionally, we received our first milestone payment from Lilly, reflecting initial progress with our collaboration, and we also received positive news of progression of one of our licensed hormone therapy products in Phase II clinical trials from our partner, BioSante Pharmaceuticals. We also received an important notice of allowance for a U.S. patent on our fast-melt tablet technology. The addition of Thomas J. Garrity and Anton Gueth to our Board of Directors provides additional industry experience and strength."


ANTARES PHARMA, INC. ANNOUNCES THAT ITS JAPANESE LICENSEE HAS OBTAINED APPROVAL FOR THE VISION FOR USE WITH HUMAN GROWTH HORMONE IN JAPAN -March 25, 2004
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that its Japanese licensee, JCR Pharmaceuticals Co. Ltd. of Ashiya, Japan, obtained regulatory approval to market Antares Pharma`s needle-free technology (Vision®) for use with human growth hormone in Japan. Possible launch dates for the product, to be known as Twin-Jector® EZ II, were not disclosed.


ANTARES PHARMA ANNOUNCES COMPLETION OF A PHASE I TRIAL FOR OXYBUTYNIN TOPICAL GEL UTILIZING ITS ATD™ GEL DELIVERY SYSTEM -March 11, 2004
Antares Pharma, Inc. (Nasdaq: ANTR) announced today the successful completion of the Phase I clinical trial for its oxybutynin topical gel product. The reported product is intended for the treatment of overactive bladder (OAB), characterized by involuntary muscle contractions leading to loss of urine. This transdermal gel formulation of oxybutynin is the first reported product that provides therapeutic levels of oxybutynin along with a significant reduction of the initial drug metabolism in the liver. The product utilizes Antares Pharma`s proprietary ATD™ gel technology designed to allow delivery of active substances across the skin. The oxybutynin formulation is a cosmetic quality, clear and odorless gel designed to be rapidly absorbed through the skin after once-a-day application on the abdomen, shoulders or thighs.


ANTARES PHARMA RAISES A TOTAL OF $14.6 MILLION IN PRIVATE EQUITY PLACEMENT -March 10, 2004
Antares Pharma, Inc. (Nasdaq: ANTR) announced today that its CEO and President, Dr. Roger G. Harrison, will be a featured speaker and presenter at the Needle-Free Injection System conference scheduled for March 24-25, 2004, in Philadelphia. The meeting will provide in-depth presentations and case studies on, among other topics, the benefits of pre-filled needle-free technologies, FDA submission strategies and challenges for needle-free injection devices, and regulatory requirements for needle-free devices. Dr. Harrison`s presentation, entitled "Technology Evolution and Regulatory Approval Process for Needle-Free Products," will address how regulatory requirements for needle-free injection technology have evolved in conjunction with the requirements of other medical devices. He will also describe the role of both the device company and the pharmaceutical company in working with regulatory agencies during the approval process.


ANTARES PHARMA RECEIVES PATENT FOR ITS EASY TEC™ FAST-MELT TECHNOLOGY-Febuary 27, 2004
Antares Pharma, Inc. (OTCBB: ANTR) announced that it received an issue notification from the U.S. Patent and Trademark Office for a patent on the formulation technology associated with its Easy Tec™ fast-melt tablet technology. The notified patent issue date was February 24, 2004, as U.S. Patent Number 6,696,085 and follows a Notice of Allowance received in November 2003.


ANTARES PHARMA RAISES A TOTAL OF $14.6 MILLION IN PRIVATE EQUITY PLACEMENT -Febuary 23, 2004
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that it raised an additional $5.1 million in its private placement of common stock at a price of $1.00 per share, bringing the total raised during the current private placement to $14,639,950. The Company issued to all purchasers five-year warrants to purchase, at an exercise price of $1.25 per share, an aggregate number of shares of common stock equal to 33% of the total number of shares of common stock sold. The transaction closed on Friday and funded today. SCO Securities LLC acted as the placement agent for the entire offering.


ANTARES PHARMA RAISES $9.55 MILLION IN PRIVATE EQUITY PLACEMENT - Febuary 10, 2004
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that it completed a $9.55 million private placement of its common stock at a price of $1.00 per share. The Company also issued to the purchasers five-year warrants to purchase, at an exercise price of $1.25 per share, an aggregate number of shares of common stock equal to 33% of the total number of shares of common stock sold. SCO Securities, LLC acted as the placement agent for this transaction, and participants included, among others, Perceptive Life Sciences Fund and SDS Merchant Fund.


ANTARES PHARMA ANNOUNCES MILESTONE PAYMENT FROM ITS LICENSING AGREEMENT WITH PFIZER -Febuary 06, 2004
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that it has received a milestone payment from Pfizer, Inc. (NYSE: PFE). The milestone payment was made in connection with a licensing agreement, originally established with Pharmacia in Europe, for a product using Antares Pharma`s Advanced Transdermal Delivery (ATD™) gel technology and was paid when the licensee achieved regulatory approval for the product in Sweden. No details of the specific product or marketing plans have been announced.


ANTARES PHARMA ANNOUNCES DEVELOPMENT AND OPTION AGREEMENT WITHPROSKELIA FOR NEW GEL PRODUCTS -January 08, 2004
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that it had signed a development and licensing option agreement with ProSkelia, SAS, a company with headquarters near Paris, France, for the development and future licensing of products utilizing Antares Pharma`s proprietary ATD™ gel technology. The products will contain an undisclosed ProSkelia proprietary compound that is currently under clinical development and will use the ATD gel technology to provide delivery of the compound. Financial terms of the agreement were not announced.


ANTARES PHARMA ANNOUNCES LICENSE AGREEMENT WITH NPMG FOR NEW TOPICAL ANESTHETIC GEL PRODUCT -January 06, 2004
Antares Pharma, Inc. (Nasdaq: ANTR) today reported a 29% increase in gross revenue to approximately $1.384 million for the third quarter ended September 30, 2003, compared to approximately $1.071 million for the same period in 2002. The increase was due primarily to license fees and royalties received in the 2003 period and none


ANTARES PHARMA ANNOUNCES MILESTONE PAYMENT FROM ITS LICENSING AGREEMENT WITH LILLY-December 09, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that it has received a milestone payment from Eli Lilly and Company (NYSE: LLY), the licensee of Antares Pharma`s needle-free injection technology in the fields of diabetes and obesity. This milestone payment followed the successful outcome of a meeting held with representatives of the Food and Drug Administration on November 6, 2003, at which the companies were able to clarify the regulatory expectations for the ongoing development program.


ANTARES PHARMA ANNOUNCES NOTICE OF ALLOWANCE FOR ITS PATENT APPLICATION-November 17 , 2003
Antares Pharma, Inc. (Nasdaq: ANTR) announced that it has received Notice of Allowance from the U.S. Patent and Trademark Office for a patent application on the formulation technology associated with its Easy Tec™ fast-melt tablet technology.


ANTARES PHARMA, INC. REPORTS THIRD QUARTER 2003 RESULTS-November 14, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today reported a 29% increase in gross revenue to approximately $1.384 million for the third quarter ended September 30, 2003, compared to approximately $1.071 million for the same period in 2002. The increase was due primarily to license fees and royalties received in the 2003 period and none received in the 2002 period. Total revenues decreased 16% to approximately $1.040 million from $1.233 million for the quarters ended September 30, 2003 and 2002, respectively. Fluctuation in gross revenue and total revenue is primarily due to the timing of receipt and earning of licensing fees and a decrease in product sales made to licensees in connection with a new product introduction in 2002. Due to significant non-operating, non-cash accounting charges relating to the conversions of debt to equity and the issuance of warrants in certain transactions, a net loss applicable to common shares of $23.345 million or $1.40 per share (diluted) for the third quarter ended September 30, 2003, compared to $2.373 million or $0.24 (diluted) per share for the third quarter 2002, was also reported. These non-cash charges increased the loss per common share by $1.26 (diluted).



ANTARES PHARMA ANNOUNCES THE ADDITION OF TWO NEW MEMBERS TO ITS BOARD OF DIRECTORS-November 03 , 2003
Antares Pharma, Inc. (Nasdaq: ANTR) announced today that two new members have joined its Board of Directors effective October 31, 2003. Mr. Anton Gueth was elected to a three-year term at the Annual Meeting of Shareholders held on October 31, 2003, and Mr. Thomas J. Garrity was appointed to a three-year term, effective October 31, 2003, to fill a vacant position on the Board.



ANTARES PHARMA ANNOUNCES ITS LICENSEE, BIOSANTE PHARMACEUTICALS, RECENTLY PRESENTED POSITIVE RESULTS FROM PHASE II TRIAL OF LIBIGEL™, A TOPICAL TESTOSTERONE GEL THAT UTILIZES ANTARES PHARMA`S GEL TECHNOLOGY SYSTEM-October 23,2003
Antares Pharma, Inc. (Nasdaq: ANTR) announced today that its U.S. licensee for its topical testosterone gel product, BioSante Pharmaceuticals, Inc. (AMEX: BPA), recently presented positive results from an ongoing Phase II clinical trial of LibiGel™ (topical testosterone gel) for the treatment of female sexual dysfunction. LibiGel utilizes Antares Pharma`s proprietary advanced transdermal delivery (ATD™) gel technology designed to allow delivery of hormones and other products across the skin.






ANTARES PHARMA ANNOUNCES A CONFERENCE CALL FOR MONDAY, SEPTEMBER 22, 2003, AT 2:00 P.M. ET
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that it would host a conference call for investors and analysts on Monday, September 22, 2003, at 2:00 p.m. (Eastern time). Antares Pharma has recently announced new financing for the Company, the conversion of all debt into Company stock, and the signing of a technology license agreement with a global pharmaceutical company. The conference call will position these changes in relation to the Company`s business model, technology platforms, future strategy and financial plans. Dr. Roger G. Harrison, CEO and President, and Lawrence M. Christian, CFO, of the Company, will host the call.

ANTARES PHARMA ANNOUNCES LICENSING AGREEMENT WITH LILLY FOR ANTARES` NEEDLE-FREE DRUG DELIVERY TECHNOLOGY- September 16, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that it had signed an exclusive license agreement with Eli Lilly and Company (NYSE: LLY) for development and use of Antares` needle-free drug delivery technology in the fields of diabetes and obesity. Additionally, Lilly retained an option for application of the technology in one other therapeutic area.


ANTARES PHARMA ANNOUNCES CONVERSION OF ALL DEBT TO EQUITY-September 15, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today announced the conversion of all existing debt to equity. The 8% Convertible Debentures held by Xmark Fund, L.P., Xmark Fund, Ltd. and SDS Merchant Fund, L.P. have been exchanged for shares of the Company`s Series D Convertible Preferred Stock. This stock is non-voting and is convertible into an aggregate of 2,437,490 shares of the Company`s common stock, the same number of shares into which the debentures were convertible. Concurrent with the closing of the transaction, the Xmark funds and SDS also agreed to terminate the security interest they held in the Company`s assets.


ANTARES PHARMA ANNOUNCES PROGRESS IN
DEVELOPMENT OF ITS NEW DEVICE PORTFOLIO-September 4, 2003
Antares Pharma, Inc. (OTCBB: ANTR) today announced that it has completed preliminary clinical testing on several of its new device products, and these devices are now available for licensing for use with specific products.


ANTARES PHARMA ANNOUNCES THAT ITS U.S. LICENSEE FOR HORMONE THERAPY (HT) PRODUCTS RAISED $10.3 MILLION IN A PRIVATE PLACEMENT TO SUPPORT CONTINUING PRODUCT DEVELOPMENT-August 25,2003
Antares Pharma, Inc. (OTCBB: ANTR) today announced that its U.S. licensee for several hormone therapy products in its transdermal gel portfolio, BioSante Pharmaceuticals, Inc. (OTCBB: BISP), announced completion of a private placement of $10.3 million on August 6, 2003. In the announcement, the CEO of BioSante indicated that the funds would be used to complete its Phase III clinical trial of Bio-E-Gel™, a transdermal estradiol product, for the treatment of menopausal symptoms and to continue development of LibiGel™, a low dose testosterone transdermal gel, for the treatment of female sexual dysfunction. Both Bio-E-Gel and LibiGel are products that use technology licensed to BioSante from Antares.


ANTARES PHARMA, INC. REPORTS SECOND QUARTER 2003 RESULTS-August 14, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today reported a 57% decrease in gross revenue to approximately $740,000 for the second quarter ended June 30, 2003, compared to approximately $1,716,000 for the same period in 2002. Total revenues decreased 20% to approximately $908,000 from $1.129 million for the quarters ended June 30, 2003 and 2002, respectively.


ANTARES PHARMA ANNOUNCES A SECOND $2.0 MILLION PRIVATE EQUITY PLACEMENT-July 22, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that it has completed the second tranche of a planned $4.0 million private placement of common equity. The second tranche of $2.0 million was under the same terms as the equity placement announced on July 9, 2003, and was also priced at the $1.00 value of Antares Pharma`s shares as of the close of business on July 3, 2003. The participants in this tranche of the financing include SCO Capital Partners LLC, North Sound Legacy Funds, and Vertical Ventures Investments LLC. SCO Securities LLC acted as the placement agent.


ANTARES PHARMA ANNOUNCES $2.0 MILLION PRIVATE EQUITY PLACEMENT-July 3, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that it completed a $2.0 million private placement of common equity at the July 3, 2003, closing price of $1.00 per share. This placement constitutes a second investment in Antares Pharma by the Xmark Funds and SDS Merchant Fund, LP.


ANTARES PHARMA EXPECTS STOCK TO TRADE ON THE OVER-THE-COUNTER BULLETIN BOARD (OTCBB)
COMPANY COMMON SHARES TO BE DELISTED FROM NASDAQ SMALLCAP MARKET EFFECTIVE WITH OPEN OF BUSINESS ON TUESDAY, JULY 1, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that a Nasdaq Listing Qualifications Panel determined to delist the Company`s securities from The Nasdaq SmallCap Market effective with the open of business on Tuesday, July 1, 2003. Previously, the Company requested an exception to certain of Nasdaq`s continued listing requirements. As part of its decision, the Panel notified the Company that its shares of common stock will be immediately eligible for quotation on the OTC Bulletin Board effective with the open of business on Tuesday, July 1, 2003, provided that a market maker enters a quote for such securities on the first day of eligibility. If this condition is satisfied, the OTC symbol assigned to the Company will be ANTR, the symbol under which it currently trades.



ANTARES PHARMA, INC. ISSUES COMMENTS ON ITS HORMONE REPLACEMENT THERAPY (HRT) PROGRAMS- June 6, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today issued a statement with regard to the continuing development of its portfolio of hormone replacement therapy products. Antares Pharma has several hormone replacement products in development, including estradiol, estradiol-progestin combination, testosterone for male hypogonadism and testosterone for the treatment of female sexual dysfunction. Certain of these have been licensed to partners for commercial development in Europe or the United States.


ANTARES PHARMA TO PRESENT AT FRIEDMAN BILLINGS RAMSEY 7TH ANNUAL TECHNOLOGY AND GROWTH INVESTOR CONFERENCE< - May 29, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) is scheduled to present at the Friedman Billings Ramsey 7th Annual Technology and Growth Investor Conference on Thursday, May 29, 2003, at 10:40 am ET. The conference will be held at the Millennium Broadway Hotel in New York City. The Company will be presenting information regarding its drug delivery technology platforms, including needle-free and mini-needle injection systems and gel formulation technology. Financial information and business projections, including the Company`s projection that the sale price of its reusable needle-free device will be $50 in 2005 (compared to $1,000 in 1976) and the Company`s projection that its revenues will increase to more than $175 million in 2008 (compared to $3.1 million in 2003), will also be presented. The Company`s reusable needle-free devices are designed to be used for a minimum of two years in their current applications. The presentation will be webcast live (audio with slide presentation) and may be accessed at www.twst.com/econf/mm/fbr2/antr.html.



ANTARES PHARMA, INC. REPORTS FIRST QUARTER 2003 RESULTS
- May 20, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today reported a 153% increase in gross revenues to $2.1 million and, after accounting for revenue deferrals, a 36% increase in total revenues to approximately $910,000 for the first quarter ended March 31, 2003, compared to approximately $669,000 for the first quarter 2002. A net loss applicable to common shares of $3.0 million or $0.26 per share for the first quarter ended March 31, 2003, compared to a net loss applicable to common shares of $2.1 million or $0.23 per share for the first quarter 2002, was also reported. The 2003 quarter included approximately $886,000 in charges relating to write-off of debt issuance discount and cost, a repurchase premium paid to the 10% debenture holders, and the excess of the fair value of warrants issued plus debenture premium over the value of the reacquired conversion feature of debentures, which increased the loss by $0.08 per common share. The Company`s net operating loss was $1.9 million and $2.2 million for the quarters ended March 31, 2003 and 2002, respectively.



ANTARES PHARMA ANNOUNCES ITS LICENSEE, BIOSANTE PHARMACEUTICALS, HAS COMPLETED PHASE II/III TRIAL FOR ESTRADIOL TOPICAL GEL UTILIZING ANTARES PHARMA`S GEL TECHNOLOGY SYSTEM
- May 16, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) announced today that its licensee for its estradiol topical gel product in the United States, BioSante Pharmaceuticals, Inc. (OTCBB: BISP), has successfully completed its Phase II/III clinical trial of Bio-E-Gel™ (estradiol topical gel) for the treatment of moderate-to-severe hot flushes in menopausal women. Bio-E-Gel utilizes Antares Pharma`s proprietary ATD™ gel technology designed to allow delivery of hormones and other products across the skin.



ANTARES PHARMA ANNOUNCES NASDAQ DELISTING NOTICE AND COMPANY`S APPEAL OF SUCH ACTION - May 1, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that it has received a notice from the Nasdaq Listing Qualifications Staff indicating that the Company fails to comply with the stockholders` equity requirements for continued listing set forth in Marketplace Rule 4310(c)(2)(B) and indicating Nasdaq`s intent to delist the Company`s common stock from the Nasdaq SmallCap Market effective at the opening of business on May 7, 2003. The Company has appealed Nasdaq`s determination by requesting an oral hearing before the Nasdaq Listing Qualifications Panel. This hearing request will stay the delisting of the Company`s common stock pending the Listing Qualifications Panel`s decision.



ANTARES PHARMA ANNOUNCES NASDAQ NOTICE OF LISTING QUALIFICATION DEFICIENCY REGARDING AUDIT COMMITTEE COMPOSITION - July 5 , 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that IKP (Institut für Klinische Pharmakologie), a leading contract research organization (CRO) located in Grunstadt, Germany, has received approval and begun the clinical study defined in the extension of Antares Pharma`s option agreement with Eli Lilly and Company (NYSE: LLY). This agreement was extended in December 2002 in order to conduct an additional clinical study to support Lilly`s evaluation of Antares Pharma`s needle-free drug delivery technology.

ANTARES PHARMA TO PRESENT AT FRIEDMAN BILLINGS RAMSEY 7TH ANNUAL TECHNOLOGY AND GROWTH INVESTOR CONFERENCE< - May 29, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) is scheduled to present at the Friedman Billings Ramsey 7th Annual Technology and Growth Investor Conference on Thursday, May 29, 2003, at 10:40 am ET. The conference will be held at the Millennium Broadway Hotel in New York City. The Company will be presenting information regarding its drug delivery technology platforms, including needle-free and mini-needle injection systems and gel formulation technology. Financial information and business projections, including the Company`s projection that the sale price of its reusable needle-free device will be $50 in 2005 (compared to $1,000 in 1976) and the Company`s projection that its revenues will increase to more than $175 million in 2008 (compared to $3.1 million in 2003), will also be presented. The Company`s reusable needle-free devices are designed to be used for a minimum of two years in their current applications. The presentation will be webcast live (audio with slide presentation) and may be accessed at www.twst.com/econf/mm/fbr2/antr.html.



ANTARES PHARMA, INC. REPORTS FIRST QUARTER 2003 RESULTS
- May 20, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today reported a 153% increase in gross revenues to $2.1 million and, after accounting for revenue deferrals, a 36% increase in total revenues to approximately $910,000 for the first quarter ended March 31, 2003, compared to approximately $669,000 for the first quarter 2002. A net loss applicable to common shares of $3.0 million or $0.26 per share for the first quarter ended March 31, 2003, compared to a net loss applicable to common shares of $2.1 million or $0.23 per share for the first quarter 2002, was also reported. The 2003 quarter included approximately $886,000 in charges relating to write-off of debt issuance discount and cost, a repurchase premium paid to the 10% debenture holders, and the excess of the fair value of warrants issued plus debenture premium over the value of the reacquired conversion feature of debentures, which increased the loss by $0.08 per common share. The Company`s net operating loss was $1.9 million and $2.2 million for the quarters ended March 31, 2003 and 2002, respectively.





ANTARES PHARMA ANNOUNCES ITS LICENSEE, BIOSANTE PHARMACEUTICALS, HAS COMPLETED PHASE II/III TRIAL FOR ESTRADIOL TOPICAL GEL UTILIZING ANTARES PHARMA`S GEL TECHNOLOGY SYSTEM
- May 16, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) announced today that its licensee for its estradiol topical gel product in the United States, BioSante Pharmaceuticals, Inc. (OTCBB: BISP), has successfully completed its Phase II/III clinical trial of Bio-E-Gel™ (estradiol topical gel) for the treatment of moderate-to-severe hot flushes in menopausal women. Bio-E-Gel utilizes Antares Pharma`s proprietary ATD™ gel technology designed to allow delivery of hormones and other products across the skin.



ANTARES PHARMA ANNOUNCES NASDAQ DELISTING NOTICE AND COMPANY`S APPEAL OF SUCH ACTION - May 1, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that it has received a notice from the Nasdaq Listing Qualifications Staff indicating that the Company fails to comply with the stockholders` equity requirements for continued listing set forth in Marketplace Rule 4310(c)(2)(B) and indicating Nasdaq`s intent to delist the Company`s common stock from the Nasdaq SmallCap Market effective at the opening of business on May 7, 2003. The Company has appealed Nasdaq`s determination by requesting an oral hearing before the Nasdaq Listing Qualifications Panel. This hearing request will stay the delisting of the Company`s common stock pending the Listing Qualifications Panel`s decision.



ANTARES PHARMA BEGINS CLINICAL TRIAL OF ITS NEEDLE-FREE DRUG DELIVERY SYSTEM UNDER THE TERMS OF PREVIOUSLY ANNOUNCED OPTION AGREEMENT WITH ELI LILLY AND COMPANY - April 14, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that IKP (Institut für Klinische Pharmakologie), a leading contract research organization (CRO) located in Grunstadt, Germany, has received approval and begun the clinical study defined in the extension of Antares Pharma`s option agreement with Eli Lilly and Company (NYSE: LLY). This agreement was extended in December 2002 in order to conduct an additional clinical study to support Lilly`s evaluation of Antares Pharma`s needle-free drug delivery technology.



ANTARES PHARMA, INC. AND GENEMEDIX PLC ANNOUNCE THEIR INTENT TO FORM A COLLABORATION TO LINK GENEMEDIX`S BIOPHARMACEUTICAL PRODUCTS WITH ANTARES PHARMA`S DEVICE TECHNOLOGIES
- March 25, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) and GeneMedix plc (LSE: GMX) today announced that its audited results for 2002 included an additional $1.0 million write-down in goodwill and an additional approximately $435,000 write-down in the carrying value of patents. The above are in addition to the $1.0 million goodwill write-down previously announced. Net loss applicable to common shares decreased 21%, to approximately $11.7 million, or $1.22 per share for 2002, compared to 2001, instead of the decrease of 31%, to approximately $10.3 million, or $1.07 per share previously announced.



ANTARES PHARMA MODIFIES PREVIOUSLY ANNOUNCED RESULTS
- March 24, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that its audited results for 2002 included an additional $1.0 million write-down in goodwill and an additional approximately $435,000 write-down in the carrying value of patents. The above are in addition to the $1.0 million goodwill write-down previously announced. Net loss applicable to common shares decreased 21%, to approximately $11.7 million, or $1.22 per share for 2002, compared to 2001, instead of the decrease of 31%, to approximately $10.3 million, or $1.07 per share previously announced.



ANTARES PHARMA REPORTS FOURTH QUARTER AND 2002 RESULTS
- March 18, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today reported a 14% increase in 2002 total revenues to $4.0 million compared to $3.5 million total revenues for fiscal 2001. Net loss applicable to common shares decreased 31% to $10.3 million or $1.07 per share for 2002, compared to a net loss applicable to common shares of $14.9 million or $1.76 per share in 2001. The net loss applicable to common shares for 2002 included a $1.0 million write-off of goodwill and approximately $1.1 million in debenture interest accretion and financing costs. Without these two items, the net loss applicable to common shares would have decreased 45% between years.



ANTARES PHARMA AND A GLOBAL PHARMACEUTICAL COMPANY EXTEND AGREEMENT TO EVALUATE ANTARES PHARMA`S PROPRIETARY MINI-NEEDLE INJECTOR - March 12, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that the agreement entered into on May 30, 2002, under which an unnamed global pharmaceutical company is evaluating Antares Pharma`s proprietary mini-needle drug delivery technology has been extended.



ANTARES PHARMA PRESENTS BEFORE THE FINANCIAL ANALYSTS AND MONEY MANAGERS SOCIETY IN NEW YORK CITY - March 04, 2003
Antares Pharma, Inc. (Nasdaq: ANTR), in an after market presentation before the Financial Analysts and Money Managers Society of New York, reported that revenues for 2002 reached approximately $4.0 million, up 14% from $3.5 million in 2001, and that the Company`s monthly burn rate has been reduced by nearly 50% from one year ago.



ANTARES PHARMA, INC. ANNOUNCES PREOGRESS IN DEVELOPMENT OF TRANSDERMAL HORMONE THERAPY (HT) GEL PRODUCTS - February 26, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) announced today the achievement of additional milestones in the development of its proprietary transdermal gel technology which simultaneously delivers estradiol and norethindrone acetate across the skin. This combination product is being developed for alleviation of vasomotor symptoms associated with menopause and has been licensed to Solvay Pharmaceuticals B.V. in Europe and BioSante Pharmaceuticals, Inc. in the United States. BioSante subsequently sub-licensed the product to Solvay Pharmaceuticals, Inc. in the United States.



ANTARES PHARMA ANNOUNCES STRATEGIC REORGANIZATION OF U.S. PRODUCTION AND DESIGN/ENGINEERING OPERATIONS - February 19, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today announced it is planning a strategic reorganization of its U.S. operations with more in-house emphasis on design and engineering advances and more outsourcing of the production of its needle-free devices. This plan will allow Antares Pharma to better utilize its technological expertise, improve cost efficiencies and reduce overhead.



ANTARES PHARMA INC. AND FERRING PHARMACEUTICALS ANNOUNCE EXTENSION OF THEIR BUSINESS RELATIONSHIP FOR USE OF NEEDLE- FREE DEVICES FOR DELIVERY OF HUMAN GROWTH HORMONE - February 12, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) and Ferring Pharmaceuticals announced today that the two companies have initiated a longer-term business relationship for the continuing development and supply of needle-free delivery devices to the human growth hormone market. Ferring currently markets the ZOMAJET® 2 VISION, Ferring`s trade name for Antares Pharma`s Medi-Jector VISION® device, for use with Ferring`s growth hormone product, ZOMACTON®. As part of the extended agreement, Ferring will access next-generation devices from Antares Pharma to further support the development of current and future markets for human growth hormone. Under the terms of the agreement, Antares Pharma will receive EURO1.5 million, including an upfront payment and the remainder within 30 days as the Company achieves preliminary targets associated with the agreement. Further financial details were not disclosed.



ANTARES PHARMA ANNOUNCES COMPLETION OF
RESTRUCTURING OF DEBT FINANCING- February 10, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that it has completed the retirement of its outstanding 10% convertible debentures issued in July 2002. This has been achieved by the Company issuing replacement senior secured convertible debentures with warrants to two of the original holders of the July 2002 debentures to cover the remaining unconverted portion of those debentures, accrued interest and a redemption payment to the other two holders of the original debentures. The replacement debentures were issued with a fixed conversion price, a longer maturity and a lower interest rate than the previous debt. As part of the restructuring, the Company issued warrants, which are callable by the Company subject to the achievement of certain milestones. Duncan Capital LLC of New York advised Antares Pharma on the debt restructuring.



ANTARES PHARMA REACQUIRES U.S. GROWTH HORMONE INJECTOR MARKET RIGHTS FROM BIO-TECHNOLOGY GENERAL CORP. - February 10, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that it has reacquired the rights for its needle-free injector technology for use with human growth hormones in the United States from Bio-Technology General Corp. Antares Pharma entered into an agreement on December 22, 1999, under which Bio-Technology General Corp. received an exclusive license to Antares Pharma`s needle-free injector technology for the U.S. growth hormone field.



ANTARES PHARMA AND ITS PROPRIETARY NEEDLE-FREE INJECTION SYSTEM, THE MEDI-JECTOR VISION®, FEATURED ON CNBC TELEVISION HEALTH CARE INNOVATION SEGMENT - February 6, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) reported that its needle-free injection system, the Medi-Jector VISION®, was featured yesterday evening on a Health Care Innovation report on CNBC television. A long-term user of the device discussed his positive experience with the VISION®, and Antares Pharma`s CEO and President, Dr. Roger G. Harrison, discussed features of the device and demonstrated its use in the four-minute segment.



ANTARES PHARMA ANNOUNCES AGREEMENT ON
RESTRUCTURING OF DEBT FINANCING - February 6, 2003
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that it has an agreement in principal to retire its outstanding 10% convertible debentures issued in July 2002. Under the pending agreement, the Company will issue replacement senior secured convertible debentures with warrants to two of the original holders of the July 2002 debentures to cover the remaining unconverted portion of those debentures, accrued interest and a redemption payment to the other two holders of the original debentures. The replacement debentures will be issued with a fixed conversion price, a longer maturity and a lower interest rate than the previous debt. As part of the pending restructuring, the Company will issue warrants, which are callable by the Company subject to the achievement of certain milestones. The Company expects to have this debt restructuring fully completed very shortly. Duncan Capital LLC of New York is advising Antares Pharma on the debt restructuring.



ANTARES PHARMA RETAINS DUNCAN CAPITAL
AS ITS INVESTMENT BANKER - February 5, 2003
Dr. Roger Harrison, CEO and President of Antares Pharma, said, "We have retained Duncan Capital to assist us in seeking additional capital as required and to help in the assessment of strategic alternatives that enable us to better develop our business prospects. Duncan Capital is a boutique firm whose executives have extensive and diverse experience in both business development and corporate finance."



ANTARES PHARMA ANNOUNCES EXTENSION TO LILLY OPTION ON ANTARES` NEEDLE-FREE TECHNOLOGY AND UPDATE ON PROGRESS IN CURRENT EVALUATION PROGRAM PROVIDED - December 16, 2002
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that the agreement entered into on February 5, 2002, under which Eli Lilly and Company (NYSE: LLY) is evaluating the application of Antares Pharma`s proprietary needle-free technology to several products in Lilly`s portfolio has been extended.



ANTARES PHARMA ANNOUNCES RESIGNATION OF DR. THOMAS RINDERKNECHT AS BOARD MEMBER - December 13, 2002
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that Dr. Thomas Rinderknecht has resigned, effective immediately, from the Board of Directors of Antares Pharma. Dr. Rinderknecht had been a member of the Board since the formation of Antares Pharma in January 2001 and had been a member of the Board of Directors of Permatec since its founding in June 1997. Explaining his decision, Dr. Rinderknecht commented that he was finding it difficult to appropriately contribute the necessary time to Antares Pharma`s Board due to personal reasons and increased business activities at the law firm Rinderknecht Klein & Stadelhofer, where he has been a partner since 1985.



ANTARES PHARMA CEO DR. ROGER HARRISON
FEATURED SPEAKER AT NEEDLE-FREE INJECTION SYSTEM CONFERENCE
- Dr. Harrison Presents "Emerging Pharmaceutical Need for
Needle-Free Devices" at International Conference on December 3, 2002
- November 25, 2002
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that its CEO, Dr. Roger Harrison, will be one of the featured speakers at the Needle-Free Injection System Conference in Philadelphia, Pennsylvania, from December 3-4, 2002. Dr. Harrison will give the opening presentation at the conference, which will also include presentations by Eli Lilly and Company, the Center for Devices and Radiological Health - U.S. Food and Drug Administration, and the Center for Disease Control, among others. Dr. Harrison`s presentation, entitled, "Examine the Emerging Pharmaceutical Need for Needle-Free Devices," will discuss the trends with today`s needle-free devices as well as the next generation of technologies and innovative advancements for both reusable and disposable injectors.



ANTARES PHARMA CEO HARRISON FEATURED
ON CNBC TELEVISION HEALTH CARE COST SEGMENT - Antares Pharma`s Medi-Jector VISION® Needle-Free Drug Delivery System
also Featured in Program - October 11, 2002
Antares Pharma, Inc. (Nasdaq: ANTR) announced today that its Chief Executive Officer and President, Roger G. Harrison, Ph.D., was interviewed for the CNBC Health Care Cost Segment on Thursday, October 10, 2002. In the interview, Dr. Harrison suggested that health care costs could be reduced if greater attention were paid to patient compliance with prescribed medication.



ANTARES PHARMA ANNOUNCES BIOSANTE PHARMACEUTICALS INITIATES PATIENT PHASE II CLINICAL TRIAL WITH TRANSDERMAL TESTOSTERONE GEL PRODUCT THAT UTILIZES ANTARES PHARMA`S GEL TECHNOLOGY SYSTEM
- October 14, 2002
Antares Pharma, Inc. (Nasdaq: ANTR) announced today that BioSante Pharmaceuticals, Inc. (OTCBB: BISP) has initiated a patient Phase II clinical trial of LibiGel™, its transdermal testosterone gel product for the treatment of female sexual dysfunction (FSD). LibiGel™ utilizes Antares Pharma`s ATD™ technology (Advanced Transdermal Delivery), an advanced gel technology platform for the delivery of drugs across the skin.



ANTARES PHARMA, INC. AND FERRING PHARMACEUTICALS A/S ANNOUNCE FORMAL LAUNCH OF ZOMAJET® 2 VISION IN EUROPE USING ANTARES PHARMA`S NEEDLE FREE INJECTION DEVICE
- October 15, 2002
announced today that Ferring has formally launched the ZomaJet® 2 Vision for its major European markets. The ZomaJet® 2 Vision, Ferring`s trade name for Antares Pharma`s Medi-Jector VISION® device, will be used to administer Ferring`s growth hormone product, Zomacton®.




ANTARES PHARMA ANNOUNCES RESIGNATION OF KEN EVENSTAD AS BOARD MEMBER - August 30, 2002
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that Kenneth Evenstad has announced his resignation, effective immediately, from the Board of Directors of Antares Pharma. Mr. Evenstad had been a member of the Board since the formation of Antares Pharma in January 2001, and had been a member of the Board of Directors of Medi-Ject Corporation, Antares Pharma`s predecessor. Explaining his decision, Mr. Evenstad commented that he was finding it difficult to appropriately contribute the necessary time to Antares Pharma`s Board due to the strong growth of Upsher-Smith Laboratories, Inc., where he has served as Chairman and Chief Executive Officer since 1969.




ANTARES PHARMA, INC. REPORTS SECOND QUARTER 2002 RESULTS
- August 6, 2002
Antares Pharma, Inc. (Nasdaq: ANTR) today reported a 22% increase in product sales to $990,555 for the second quarter ended June 30, 2002, compared to $813,354 for the same period in 2001. Total revenues increased 2% to $1.129 million from $1.106 million for the quarters ended June 30, 2002 and 2001, respectively, primarily due to the timing of earning licensing fees. A net loss applicable to common shares of $1.967 million or $0.21 per share for the second quarter ended June 30, 2002, compared with a net loss applicable to common shares of $1.729 million or $0.20 per share for the second quarter 2001, was also reported.




ANTARES PHARMA ANNOUNCES COMPLETION OF INITIAL FUNDING
- July 15, 2002
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that it has closed on $2 million of its private placement of 10% convertible debentures. This placement constitutes the initial funding of a possible $12 million financing with a group of institutional investors. Spencer Trask Ventures, Inc., coordinated the fund raising effort.




MAJORITY SHAREHOLDER CONVERTS SHORT-TERM LOAN INTO COMMON STOCK AT MARKET PRICE - June 25, 2002
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that its major shareholder, Dr. Jacques Gonella, has converted the $2 million term note from the Company into Antares Pharma common stock at the market price as of June 10, 2002. The Company`s Board of Directors approved this transaction at its June 20, 2002, meeting.




ANTARES PHARMA ANNOUNCES ANNUAL MEETING WEBCAST - June 14, 2002
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that it will host a live webcast of its Annual Meeting of Shareholders which is being held on Thursday, June 20, 2002 at 10:00 am (EDT) at the Omni Hotel at Independence Park in Philadelphia, Pennsylvania.




Antares Pharma, Inc. and Ferring Pharmaceuticals A/S Announce Ferring`s Introduction of the Medi-Jector VISION® for use with Zomacton® Under the Trade Name ZomaJet® 2 Vision - June 12, 2002
Antares Pharma, Inc. (Nasdaq: ANTR) announced today that Ferring Pharmaceuticals A/S, its partner in Europe for the use of the Medi-Jector Choice® needle-free injection system in association with its human growth hormone product (Zomacton®), has disclosed its plan to introduce the Medi-Jector VISION® device for the same application under the trade name ZomaJet® 2 Vision. Specific launch plans in Ferring`s market regions were not disclosed.




ANTARES PHARMA AND GLOBAL PHARMACEUTICAL COMPANY SIGN AGREEMENT TO EVALUATE ANTARES PHARMA`S PROPRIETARY MINI-NEEDLE INJECTOR- June 06, 2002
Antares Pharma, Inc. (Nasdaq: ANTR) today announced that it has entered into an evaluation agreement with an unnamed global pharmaceutical company for Antares Pharma`s mini-needle drug delivery technology.




ANTARES PHARMA, INC. AND JCR PHARMACEUTICALS CO. LTD. ANNOUNCE AGREEMENT FOR JCR TO USE THE MEDI-JECTOR VISION® FOR ADMINISTRATION OF HUMAN GROWTH HORMONE IN JAPAN - May 08, 2002
Antares Pharma, Inc. (Nasdaq: ANTR), based in Exton, Pennsylvania, and JCR Pharmaceuticals Co. Ltd of Ashiya, Japan, today announced that JCR has exercised its option under an existing agreement with Antares Pharma for the use of Antares Pharma`s Medi-Jector VISION® needle-free delivery device for administration of human growth hormone in Japan. This reusable device has been available in the United States for the administration of insulin since 1999.




ANTARES PHARMA, INC. REPORTS FIRST QUARTER 2002 RESULTS
- April 30, 2002
Antares Pharma, Inc. (Nasdaq: ANTR) today reported a 14% increase in total revenues to $0.669 million for the first quarter ended March 31, 2002, compared to $0.587 million for the first quarter 2001. A net loss applicable to common shares of $2.2 million or $0.24 per share for the first quarter ended March 31, 2002, compared with a net loss applicable to common shares of $8.0 million or $1.14 per share for the first quarter 2001 was also reported. The 2001 quarter included a $5.314 million in-the-money conversation feature to certain preferred shareholders, which increased the loss by $0.76 per common share. The Company`s net loss was $2.7 and $2.2 million for the quarters ended March 31, 2001 and 2002, respectively.




ANTARES PHARMA, INC. AND INNOJECT, INC. ANNOUNCE COLLABORATION TO INCORPORATE INNOJECT`S INJECTION DEVICE INTO ANTARES PHARMA`S BUSINESS DEVELOPMENT PORTFOLIO - POTENTIAL FOR ADDITIONAL PHARMA PARTNERSHIP AGREEMENTS FOR BOTH COMPANIES IS ENHANCED
- April 25, 2002
Antares Pharma, Inc. (Nasdaq: ANTR) and Innoject, Inc, a Texas-based medical device company, today announced an agreement in which Antares Pharma will incorporate the innovative automatic retractable injection devices from Innoject into its business development portfolio. Innoject will retain ownership of the product while Antares Pharma will derive benefits from successfully completed business development arrangements. Financial terms of the agreement have not been disclosed.



ANTARES PHARMA, INC. APPOINTS DAVID KIRK AS SENIOR DIRECTOR OF BUSINESS DEVELOPMENT - April 24, 2002
Antares Pharma, Inc. (Nasdaq: ANTR), based in Exton, Pennsylvania, announced that it has added to its business development staff by appointing David Kirk as Senior Director of Business Development. Mr. Kirk brings over 20 years of pharmaceutical industry experience to the Company, having served in senior management positions with emphasis on business development, licensing and marketing with Johnson & Johnson, Bayer and Roche. Prior to joining Antares Pharma, he served most recently as Director of Licensing and Business Development for Bioglan Pharma, Inc.



ANTARES PHARMA, INC. ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM SOLVAY PHARMACEUTICALS BV - April 23, 2002
Antares Pharma, Inc. (Nasdaq: ANTR) based in Exton, Pennsylvania, today announced the receipt of a milestone payment from Solvay Pharmaceuticals in connection with the continuing clinical development of an estrogen/progestin combination transdermal gel product using Antares Pharma`s proprietary Combi Gel™ technology.



PRELIMINARY DATA SUGGESTS NEW CARTRIDGE-BASED
NEEDLE-FREE INJECTION SYSTEM IS SAFE AND EFFECTIVE - April 17, 2002
Antares Pharma, Inc. (ANTR) today announced the results of preliminary human clinical studies performed with a new needle-free injection system that the Company is developing. The new injector is unique in that it incorporates a drug-filled cartridge into the device for ease of use.



ANTARES PHARMA, INC. AND MACROMED INCORPORATED COLLABORATE TO DEVELOP PATIENT-FRIENDLY DEPOT DELIVERY SYSTEMS - March 19, 2002
Antares Pharma (Nasdaq: ANTR) based in Exton, Pennsylvania, and MacroMed, Inc., a private company based in Salt Lake City, Utah, today announced a technology and business development collaboration. In this arrangement, the companies will work together to optimize MacroMed`s ReGel® sustained release gel technology for use with Antares Pharma`s needle-free and mini-needle injection technologies.



ANTARES PHARMA, INC. REPORTS FOURTH QUARTER AND 2001 RESULTS
- , March 15, 2002
Antares Pharma, Inc. today reported a six-fold increase in total revenues to $1.2 million for the fourth quarter ended December 31, 2001, compared to $0.2 million for the fourth quarter 2000. A net loss of $3.1 million or $0.33 per share for the fourth quarter ended December 31, 2001, compared with a net loss of $0.9 million or $0.22 per share for fourth quarter 2000 was also reported.




PRELIMINARY DATA SUGGESTS THERAPEUTIC ADVANTAGE OF NEEDLE-FREE INSULIN DELIVERY - February 12, 2002
Antares Pharma, Inc. (NASDAQ: ANTR) today announced results of preliminary studies performed with the Medi-Jector VISION® needle-free injection system by Dr. Mario Velussi, Casa di Cura, Aurisina, Italy. Dr. Velussi presented data concerning the management of blood sugar levels in fifteen patients at a diabetes therapy conference in San Mateo, California.



ANTARES PHARMA SIGNS EVALUATION AGREEMENT WITH ELI LILLY AND COMPANY - February 5, 2002
Antares Pharma, Inc. (NASDAQ: ANTR) today announced that Eli Lilly and Company has entered into an option and evaluation agreement for Antares Pharma`s needle-free drug delivery technology for several undisclosed products.


ANTARES PHARMA, INC., ENTERS EVALUATION AGREEMENT ON EASY-TEC™ TECHNOLOGY - January 22, 2002
Antares Pharma, Inc. (NASDAQ: ANTR) today announced that it has entered into a non-exclusive evaluation agreement with an unnamed U.S. based company for Antares Pharma`s fast-dissolve oral drug delivery technology, Easy-Tec. Financial terms of the agreement were not disclosed.


ANTARES PHARMA, INC., LICENSES RIGHTS TO HORMONE PRODUCT TO BIOSANTE PHARMACEUTICALS, INC. - , January 8, 2002

Antares Pharma, Inc. (NASDAQ: ANTR) today announced a license agreement with BioSante Pharmaceuticals, Inc. (OTCBB: BTPH) in which BioSante licensed from Antares Pharma development and marketing rights to a hormone replacement gel for use by women.


ANTARES PHARMA OPENS NEW CORPORATE HEADQUARTERS IN EXTON, PENNSYLVANIA - , December 17, 2001


Antares Pharma (Nasdaq: ANTR) today announced that it has opened its new corporate headquarters in Exton, Pennsylvania, a suburb of Philadelphia known for its prominent high-tech/biotech industry commercial corridor.


ANTARES PHARMA NAMES JACQUES F. REJEANGE AND JOHN S. GOGOL
TO BOARD OF DIRECTORS- , November 28, 2001


Antares Pharma (Nasdaq: ANTR) today named Jacques F. Rejeange and John S. Gogol to the Company`s Board of Directors, bringing the total number of directors to ten.


ANTARES PHARMA AND SCITECH MEDICAL PRODUCTS COLLABORATE TO DEVELOP HORMONE REPLACEMENT THERAPY PRODUCTS - , November 15, 2001



Antares Pharma, Inc. (NASDAQ: ANTR), today announced a license agreement with SciTech Medical Products, Ltd., for the development and marketing of two (2) hormone replacement therapy products in specific Asian Pacific markets. These products will address a variety of hormone deficiencies affecting both men and women. The growing market in this Asia Pacific region is currently believed to exceed $100 million (U.S. dollars).


ANTARES PHARMA, INC. REPORTS THIRD QUARTER RESULTS - , November 5, 2001



Antares Pharma, Inc. (Nasdaq: ANTR) today reported a three-fold increase in total revenues to $596,757 for the third quarter ended September 30, 2001, compared to $133,981 in the year-ago quarter. A net loss of $2,156,890 or $0.24 per share for the third quarter ended September 30, 2001, compared with a net loss of $958,898 or $0.22 per share in the year-ago quarter was also reported.


JS200

[pagitz01]

bin dabei seit 1.49 usd...

[Hufeland]

Ich mit einer kleinen Position seit 1,73 $, direkt in USA gekauft.

Hufeland

[js200]

Ich warte auf einen Rücksetzer

Die 200% waren zuviel die letzten 2 Monate

JS200

[js200]

ANTARES PHARMA INC (:AIS)

Ab heute gilt das Neue SYMBOL

Ab Heute an der AMEX

JS200

[js200]

BPA: Conf Call to Discuss Positive Data for LibiGel

Thursday , September 23, 2004 07:02 ET

BioSante Pharmaceuticals, Inc. (Amex: BPA) announced it will hold a conference call at 8:45 AM ET today to discuss positive results of its Phase II clinical study investigating LibiGel(TM) for the treatment of female sexual dysfunction (FSD).

The U.S./Canada dial-in number is 1-877-407-9205.

The international dial-in number is 1-201-689-8054.

A recording of the conference call will be available two hours after completion, and will be available until September 29, 2004 at 11:59 PM ET at 1-877-660-6853 (U.S.) and 1-201-612-7415 (International).

The conference account number is 1628, and the ID number is 118868.

A real-time, listen-only webcast of the call can be accessed from the BioSante Pharmaceuticals website, and will be available until December 22, 2004 at 11:59 PM ET at www.biosantepharma.com. Listeners should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

Misc Releated Info:
** Original Confirmation

JS200

[js200]

09/23/2004 (09:51 ET) AIS: AMEX Lists Antares Pharma, Inc. Ticker Symbol - Knobias
09/23/2004 (09:48 ET) American Stock Exchange Lists Common Stock of Antares Pharma, Inc. - PR Newswire
09/22/2004 (15:01 ET) ANTR: BioSante Announces Positive Phase 2 Results of LibiGel - Knobias
09/22/2004 (14:55 ET) Antares Pharma`s (OTCBB: ANTR / Amex: AIS as of September 23, 2004) North American Licensee BioSante Pharmaceuticals, Inc. Announces Positive Results of Phase II Study of LibiGel(TM), Topical Testosterone Gel - PR Newswire
09/22/2004 (10:11 ET) ANTR: Volume Spike; 9% > 20-adsv, Stock +8.75% - Knobias


JS200

[Hufeland]

Wird die Aktie heute nicht gehandelt, oder geht mein Scotti nicht?

Ist RT 1,55 richtig?


Hufeland

[js200]

Gehandelt wird

Kurs : 1,6885-------> 1.000 Teile

Volumen : 463.000

JS200

[js200]

Wie von mir erwartet

Last Trade: 1.630 Change: -0.070 (-4.118%)
Previous Close: 1.700 Volume: 614,700
Bid: N/A Ask: N/A
Today`s Open: 1.800 # of Trades: 107

JS200

[js200]

ANTR OTCBB Deletion Eff. 09/23/2004
via CDS

September 23, 2004

Antares Pharma, Inc. Common Stock (ANTR) will be deleted effective 09/23/2004.



Comments: Listed on AMEX (AIS)**


This information can be viewed at http://www.otcbb.com/dailylist/history/bbdl_09222004.stm


Tel: [phone] OTCBB Hotline (BB)

JS200

[js200]

Antares Pharma to Present at UBS Global Life Sciences Conference
via COMTEX

September 24, 2004

EXTON, Pa., Sep 24, 2004 /PRNewswire-FirstCall via COMTEX/ --

Antares Pharma, Inc. (Amex: AIS), an evolving specialty pharmaceutical company with headquarters in Exton, Pennsylvania, announced today that it will participate in the UBS Global Life Sciences Conference in New York City on Tuesday, September 28, 2004, at 10:00 am Eastern.

"The UBS Global Life Sciences Conference is widely known as one of the premier healthcare conferences," said President and CEO, Jack E. Stover. "We are proud to be selected as a presenter and as a representative of the specialty pharma sector," Mr. Stover added.

The conference will be held at The Grand Hyatt Hotel in New York City. Antares Pharma`s presentation will be webcast live for investors at http://www.ibb.ubs.com and will be available for a period of 30 days following the conference.

The UBS Global Life Sciences Conference is expected to include approximately 300 presenting companies with an audience of more than 3,000 attendees.

About Antares Pharma

Antares Pharma is an emerging specialty pharmaceutical company leveraging its experience in drug delivery systems to enhance product performance of established and developing drugs. The Company`s current technology platforms include transdermal (Advanced Transdermal Delivery ATD(TM)) gels, disposable mini-needle injection systems (Vibex(TM)), reusable needle-free injection systems (VISION(R) and Valeo(TM)), and fast-melt oral (Easy Tec(TM)) tablets. The Company currently has active partnering programs with several pharmaceutical and distribution companies for a number of indications and applications, including diabetes, growth disorders, obesity, female sexual dysfunction and other hormone therapy.

Antares Pharma currently distributes its needle-free injector systems in more than 20 countries and markets the same technology for use with human growth hormone through licensees in most major regions of the world. Licensees also market an ibuprofen gel using Antares Pharma`s ATD(TM) technology in several major European countries. In addition, Antares Pharma is undertaking development or is conducting research on several product opportunities that will form the basis of its specialty pharma program. Antares Pharma`s corporate headquarters is in Exton, Pennsylvania, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company`s reports filed with the U.S. Securities and Exchange Commission. Antares Pharma claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

For more information, visit Antares Pharma`s web site at http://www.antarespharma.com. Information included on the Company`s website is not incorporated herein by reference or otherwise.

SOURCE Antares Pharma, Inc.

Jack E. Stover, CEO and President, [phone], or Lawrence M. Christian, CFO and Vice President - Finance, [phone], both of Antares Pharma; or Ira Weingarten/Steve Chizzik of Equity Communications, [phone], for Antares Pharma http://www.antarespharma.com

Copyright (C) 2004 PR Newswire. All rights reserved.

JS200

[js200]

09/27/2004 (11:49 ET) Antares Pharma, Inc. Named One of Delaware Valley`s Fastest Growing Technology Companies in Deloitte`s Technology Fast 50 Program - PR Newswire
09/24/2004 (09:01 ET) Antares Pharma to Present at UBS Global Life Sciences Conference - PR Newswire
09/23/2004 (09:51 ET) AIS: AMEX Lists Antares Pharma, Inc. Ticker Symbol - Knobias
09/23/2004 (09:48 ET) American Stock Exchange Lists Common Stock of Antares Pharma, Inc. - PR Newswire
09/22/2004 (15:01 ET) ANTR: BioSante Announces Positive Phase 2 Results of LibiGel - Knobias

JS200

[js200]

Last Trade: 1.500 Change: 0.030 (+2.041%)
Previous Close: 1.470 Volume: 394,400
Bid: N/A Ask: N/A
Today`s Open: 1.500 # of Trades: 60

[js200]

Last Trade: 1.360 Change: -0.140 (-9.333%)
Previous Close: 1.500 Volume: 217,600
Bid: N/A Ask: N/A
Today`s Open: 1.540 # of Trades: 161

So nun komm schön dahin, wo ich dich haben möchte

JS200

[js200]

Antares Pharma Announces Phase III Clinical Trial Update On Its Estradiol Advanced Transdermal Delivery (ATD(TM)) Gel By North American Licensee
via COMTEX

October 7, 2004

EXTON, Pa., Oct 7, 2004 /PRNewswire-FirstCall via COMTEX/ --

Antares Pharma, Inc. (Amex: AIS), an evolving specialty pharmaceutical company with headquarters in Exton, Pennsylvania, today announced an update regarding the ongoing pivotal Phase III clinical trial of its estradiol Advanced Transdermal Delivery (ATD(TM)) gel licensed in North America to BioSante Pharmaceuticals, Inc. (Amex: BPA) and called Bio-E-Gel(TM) for the treatment of moderate-to-severe hot flashes and vaginal atrophy in menopausal women. While Antares Pharma has licensed its estradiol gel in its patented ATD(TM) system in North America and certain other territories, Antares Pharma retains all rights to utilize and reference all data obtained from clinical trials to develop, market and license its estradiol ATD(TM) gel in Europe, Japan and other important markets.

It was reported that the Phase III trial is on track to enroll all subjects by year-end 2004 and is planned to be completed by the end of the first quarter 2005. A new drug application (NDA) is expected to be filed as soon as possible after completion of the trial. The Phase III clinical trial is testing three doses of Bio-E-Gel(TM) to maximize the safety profile by identifying the lowest effective dose and thereby determining the safest dose, avoiding the need for a Phase IV trial or label restriction. Strong subject interest in participating in the Phase III clinical trial is believed to be a reflection of the need for a more natural estrogen therapy that overcomes many of the undesirable effects of current estrogen therapies.

"We are pleased with the progress BioSante has reported, and we look forward to the completion of the Phase III trial and submission of an NDA," said Jack E. Stover, President and CEO of Antares Pharma. "Antares Pharma can now formalize its own plans for regulatory submission and commercialization of its estradiol ATD(TM) gel in the rest of the world."

About Antares Pharma

Antares Pharma is an emerging specialty pharmaceutical company leveraging its experience in drug delivery systems to enhance product performance of established and developing drugs. The Company`s current technology platforms include transdermal (Advanced Transdermal Delivery ATD(TM)) gels, disposable mini-needle injection systems (Vibex(TM)), reusable needle-free injection systems (VISION(R) and Valeo(TM)), and fast-melt oral (Easy Tec(TM)) tablets. The Company currently has active partnering programs with several pharmaceutical and distribution companies for a number of indications and applications, including diabetes, growth disorders, obesity, female sexual dysfunction and other hormone therapy.

Antares Pharma currently distributes its needle-free injector systems in more than 20 countries and markets the same technology for use with human growth hormone through licensees in most major regions of the world. Licensees also market an ibuprofen gel using Antares Pharma`s ATD(TM) technology in several major European countries. In addition, Antares Pharma is undertaking development or is conducting research on several product opportunities that will form the basis of its specialty pharma program. Antares Pharma`s corporate headquarters is in Exton, Pennsylvania, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company`s reports filed with the U.S. Securities and Exchange Commission. Antares Pharma claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

For more information, visit Antares Pharma`s web site at http://www.antarespharma.com. Information included on the Company`s website is not incorporated herein by reference or otherwise.

SOURCE Antares Pharma, Inc.

Jack E. Stover, CEO and President, [phone], or Lawrence M. Christian, CFO and Vice President - Finance, [phone], both of Antares Pharma; or Ira Weingarten/Steve Chizzik of Equity Communications, [phone], for Antares Pharma http://www.antarespharma.com

Copyright (C) 2004 PR Newswire. All rights reserved.

[js200]

10/14/2004 (12:10 ET) AIS: Receives European Patent for Easy Tec(TM) Technology - Knobias
10/14/2004 (12:07 ET) Antares Pharma Receives European Patent For Easy Tec(TM) Fast-Melt Technology - PR Newswire
10/07/2004 (15:48 ET) AIS/BPA: Antares Announces Phase III Trial Update on ATD Gel - Knobias
10/07/2004 (15:44 ET) Antares Pharma Announces Phase III Clinical Trial Update On Its Estradiol Advanced Transdermal Delivery (ATD(TM)) Gel By North American Licensee - PR Newswire
09/28/2004 (09:58 ET) AIS: Slides Utilized at UBS Global Life Sciences Conference - Knobias


JS200

[js200]

Last Trade: 1.250 Change: 0.050 (+4.167%)
Previous Close: 1.200 Volume: 106,700
Bid: N/A Ask: N/A
Today`s Open: 1.250 # of Trades: 29

[js200]

Last Trade: 1.250 Change: 0.050 (+4.167%)
Previous Close: 1.200 Volume: 174,700
Bid: N/A Ask: N/A
Today`s Open: 1.230 # of Trades: 53

[js200]

Last Trade: 1.380 Change: 0.130 (+10.400%)
Previous Close: 1.250 Volume: 323,900
Bid: N/A Ask: N/A
Today`s Open: 1.250 # of Trades: 168

JS200

[js200]

10/21/2004 (16:13 ET) AIS: Short Interest UP 100.0% to 397.2K in Oct 2004 - Knobias
10/14/2004 (12:10 ET) AIS: Receives European Patent for Easy Tec(TM) Technology - Knobias
10/14/2004 (12:07 ET) Antares Pharma Receives European Patent For Easy Tec(TM) Fast-Melt Technology - PR Newswire
10/07/2004 (15:48 ET) AIS/BPA: Antares Announces Phase III Trial Update on ATD Gel - Knobias
10/07/2004 (15:44 ET) Antares Pharma Announces Phase III Clinical Trial Update On Its Estradiol Advanced Transdermal Delivery (ATD(TM)) Gel By North American Licensee - PR Newswire

[js200]

Last Trade: 1.400 Change: 0.000 (+0.000%)
Previous Close: 1.400 Volume: 135,300
Bid: N/A Ask: N/A
Today`s Open: 1.410 # of Trades: 38

[js200]

10/25/2004 (13:00 ET) AIS: Filed New Form 4 - Edgar
10/25/2004 (12:52 ET) AIS: Filed New Form 4 - Edgar
10/25/2004 (12:47 ET) AIS: Filed New Form 4 - Edgar
10/25/2004 (12:03 ET) AIS: Filed New Form 4 - Edgar
10/25/2004 (11:49 ET) AIS: Filed New Form 4 - Edgar

[js200]

CURRENT BUSINESS INFORMATION: Antares Pharma is a drug delivery company focused on developing, manufacturing and marketing needle-free injection systems for the self-administration of a wide range of parenteral (injectable) drugs. The Company makes a small spring-action device and the attached disposable plastic syringes to hold the drug. A liquid drug is drawn up into the syringe through a small hole at the end. When the syringe is held against the body and the spring is released, a piston drives the fluid stream into the tissues beneath the skin. A person may re-arm the device and repeat the process or attach a new sterile syringe between injections. Recently the Company developed a variation of the jet injector by adding a very small hidden needle to a pre-filled, single-use injector.

JS200

[js200]

Arbios Appoints Jack E. Stover as Board Member

Thursday , November 04, 2004 08:30 ET

LOS ANGELES, Nov 4, 2004 (BUSINESS WIRE) -- Arbios Systems, Inc. (OTC BB: ABOS), a biomedical device company engaged in the development of proprietary liver assist technologies useful in the treatment of acute liver failure, is pleased to announce that Jack E. Stover was appointed a Director of the Company on November 2, 2004.

Mr. Stover is currently the President, CEO and Director of Antares Pharma Inc. (AMEX: AIS), an emerging specialty pharmaceutical company whose products and technologies include transdermal gels, fast-melt oral tablets and mini-needle and needle-free injector systems.

Prior to joining Antares, Mr. Stover was the Executive Vice President, CFO and Treasurer of SICOR, Inc., the largest publicly-held vertically integrated specialty, injectable pharmaceutical company that was recently sold to Teva Pharmaceuticals for in excess of $3.4 billion. Prior to Sicor Mr. Stover was Executive Vice President and Director of Gynetics, Inc. a privately held women`s health care company developing and marketing proprietary drugs and devices.

Mr. Stover also served as Senior Vice President, Chief Financial Officer, Chief Information Officer and Director for B. Braun Medical, an international medical products and pharma company where he led the Company`s first private placement and its largest acquisition, a pharmaceutical division of Ivax Corp for in excess of $250 million.

For over 16 years Mr. Stover was an employee and then a partner with Pricewaterhouse Coopers (formerly Coopers & Lybrand) where he was Partner- in- Charge of the LifeSciences Practice in New Jersey.

Mr. Stover earned a Bachelors degree in Business in 1975 from Lehigh University and is a certified public accountant.

Commenting on the appointment Dr. Jacek Rozga, President of Arbios Systems, stated, "We are delighted to have Jack on the Arbios board. I believe Jack`s vast knowledge and skills, especially within the healthcare industry, will be highly beneficial to Arbios as we progress toward commercialization of the products we are currently developing."

About Arbios

Arbios Systems, Inc. is a biomedical device company that, through its wholly-owned subsidiary, Arbios Technologies, Inc., is engaged in the discovery, acquisition and development of proprietary liver assist devices and new technologies useful in the diagnosis and treatment of acute liver failure. Arbios` products in development include SEPET(TM), a novel blood purification therapy employing selective plasma filtration therapy, HepatAssist-2(TM), a bioartificial liver based on technology recently acquired from Circe Biomedical, Inc., and LIVERAID(TM), a bioartificial liver in which liver cell therapy and sorbent-based hemodiafiltration are integrated in the company`s proprietary three-compartment cartridge with fiber-in-fiber geometry.

At present no effective direct treatment for liver failure is available, and patients must receive a liver transplant or endure prolonged hospitalization with a significant mortality rate. However, only a small percentage of liver failure patients receive a transplant due to shortage of donor livers. Further, many patients cannot be transplanted because of alcohol or drug abuse, infection, cancer, cardiovascular disease, etc. There is, therefore, an urgent need for artificial means of liver assistance to facilitate recovery from liver failure without a transplant.

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Further discussion of these and other potential risk factors may be found in Arbios` latest filings with the Securities and Exchange Commission on Form 10-KSB, and any subsequent updates thereto on form 10-QSB. These forward-looking statements speak only as of the date hereof. Arbios disclaims any obligation to update these forward-looking statements.

SOURCE: Arbios Systems, Inc.


CONTACT: Arbios Systems, Inc.
Amy Factor, 973-377-7665
[e-mail]
or
Wolfe Axelrod Weinberger Associates LLC
Donald C. Weinberger, 212-370-4500
Fax: [phone]
[e-mail]
or
Media:
Andria Arena, 212-370-4500
Fax: [phone]



Copyright (C) 2004 Business Wire. All rights reserved.


-0-


KEYWORD: NEW YORK
INDUSTRY KEYWORD: BIOTECHNOLOGY
PHARMACEUTICAL
MEDICAL
MANAGEMENT
CHANGES
Copyright
Business
Wire
2004


STOCK SYMBOLS: [(abos)]

[js200]

New Data Highlights Key Advantages of Antares Pharma`s ATD(TM) Gel Technology When Compared to Transdermal Patches
via COMTEX

November 4, 2004

EXTON, Pa., Nov 4, 2004 /PRNewswire-FirstCall via COMTEX/ --

Antares Pharma, Inc. (Amex: AIS), a specialty pharmaceutical company that develops and licenses drug delivery technology for the next generation lifestyle products sector, said today that new Phase II data on LibiGel(TM), a gel formulation of testosterone, being developed by BioSante Pharmaceuticals, Inc. (Amex: BPA) highlighted key advantages of Antares Pharma`s Advanced Transdermal Delivery (ATD(TM)) gel technology when compared with a transdermal testosterone patch delivery system.

Phase II data on LibiGel(TM), as reported by Antares Pharma`s licensee, BioSante, indicated minimal application site irritation in contrast to previous trials with a transdermal testosterone patch delivery system in which approximately 30 percent of subjects reported such reactions. Additionally, LibiGel(TM) produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group with no serious adverse effects observed.

"Antares Pharma believes its proprietary ATD(TM) gel technology offers compelling advantages compared with transdermal patches, such as Intrinsa(R), and that these advantages include not only the lack of irritation associated with occlusion and response to adhesives but also cost, efficiency of delivery and cosmetic elegance," according to Antares Pharma`s President and CEO, Jack E. Stover. Stover also added, "We believe that the data emerging from clinical trials of LibiGel(TM), while still early, confirm our expectations that LibiGel(TM) will compare favorably on all important dimensions."

BioSante recently announced new Phase II clinical data on LibiGel(TM) that was presented before the International Society for the Study of Women`s Sexual Health (ISSWSH) Annual Meeting in Atlanta on October 30, 2004. Pursuant to its agreement with BioSante, Antares Pharma expects to receive milestone payments from BioSante at certain stages of development and royalties from end sales of LibiGel(TM) in North America. Importantly, also pursuant to this agreement, Antares Pharma has rights to the clinical data generated by BioSante to independently submit for regulatory approval and marketing the testosterone gel for the treatment of female sexual dysfunction in other territories, including Europe and Japan.

Antares Pharma believes its proprietary ATD(TM) single and combination gels are safe, patient friendly, easy to use and highly attractive new methods of drug delivery. Antares Pharma`s ATD(TM) gels utilize a combination of permeation enhancers and further bolster a pharmaceutical agent`s ability to penetrate the skin. This new generation of product leads to a sustained plasma profile of the active agent without the irritation and cosmetic concerns often associated with patches. Presently, Antares Pharma markets, through its licensees, an ibuprofen gel for localized pain relief in 11 countries throughout the world and is currently evaluating entering markets in North America. In addition to its testosterone gel for women that has been licensed to BioSante in North America and other territories, Antares Pharma has also licensed to BioSante, in North America and other territories, an estradiol gel to treat hot flashes and vaginal atrophy (known as Bio-E-Gel(TM) in the U.S.) and a combination estradiol and progestin gel for hormone therapy that has also been licensed to Solvay Pharmaceuticals, B.V. Additionally, Antares Pharma is developing its own ATD(TM) oxybutynin gel for overactive bladder disorder, as well as other products.

About Antares Pharma

Antares Pharma is a specialty pharma company focused on the growing lifestyle products sector and committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new products and devices. The Company`s current technology platforms include its transdermal Advanced Transdermal Delivery (ATD(TM)) gels, fast-melt (Easy Tec(TM)) oral tablet technology, disposable mini-needle injection systems (Vibex(TM)), and reusable needle-free injection systems (VISION(R) and Valeo(TM)). The Company currently has active partnering programs with several pharmaceutical and distribution companies for a number of indications and applications, including diabetes, growth disorders, obesity, female sexual dysfunction and other hormone therapy.

Antares Pharma currently distributes its needle-free injector systems in more than 20 countries and markets the same technology for use with human growth hormone through licensees in most major regions of the world. Licensees also market an ibuprofen gel using Antares Pharma`s ATD(TM) technology in several major European countries. In addition, Antares Pharma is undertaking development or is conducting research on several product opportunities that will form the basis of its specialty pharma program. Antares Pharma`s corporate headquarters is in Exton, Pennsylvania, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company`s reports filed with the U.S. Securities and Exchange Commission. Antares Pharma claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

For more information, visit Antares Pharma`s web site at http://www.antarespharma.com. Information included on the Company`s website is not incorporated herein by reference or otherwise.

SOURCE Antares Pharma, Inc.

Jack E. Stover, President and CEO, [phone], or Lawrence M. Christian, CFO and Vice President-Finance, [phone], both of Antares Pharma; or Steve Chizzik or Ira Weingarten of Equity Communications, [phone] http://www.antarespharma.com

Copyright (C) 2004 PR Newswire. All rights reserved.

Print story

Current Quote

AMX: BPA
Biotech/Medical

Last: 8.900
Change: N/A
Volume: N/A
Day High: N/A
Day Low: N/A



First Alert News
Get real-time BPA release alerts by entering your email address below.

JS200

[js200]

Last Trade: 1.350 Change: 0.150 (+12.500%)
Previous Close: 1.200 Volume: 373,000
Bid: N/A Ask: N/A
Today`s Open: 1.250 # of Trades: 70

[js200]

11/08/2004 (15:06 ET) Antares Pharma to Present at CIBC Healthcare Conference - PR Newswire
11/08/2004 (07:15 ET) TABLE: Unconfirmed Earnings Expected Saturday, Nov 13 - Knobias
11/05/2004 (16:21 ET) AIS: Jumps +6.30%; Vol +75%; Last 90 Min of Trading - Knobias
11/04/2004 (15:11 ET) AIS: Volume Spike; 63% > 20-adsv, Stock -4.00% - Knobias
11/04/2004 (09:15 ET) New Data Highlights Key Advantages of Antares Pharma`s ATD(TM) Gel Technology When Compared to Transdermal Patches - PR Newswire

[js200]

Antares Pharma, Inc. Reports Third Quarter 2004 Results
via COMTEX

November 15, 2004

Progress in Product Development, New Management and
Cost Controls Highlight Quarter

EXTON, Pa., Nov 15, 2004 /PRNewswire-FirstCall via COMTEX/ --

Antares Pharma, Inc. (Amex: AIS), a specialty pharmaceutical company focused on the growing lifestyle products sector, today announced financial results for the third quarter 2004.

Third Quarter 2004 and Recent Operational Highlights -- Positive results in Phase II study of ATD(TM) testosterone gel (LibiGel(TM)) announced by North American licensee: The Company`s transdermal ATD(TM) testosterone gel significantly increases sexual activity in surgically menopausal women suffering from female sexual dysfunction (FSD) -- Phase III clinical trial update on estradiol ATD(TM) gel (Bio-E- Gel(TM)) announced by North American licensee: Phase III trial for treatment of moderate-to-severe hot flashes and vaginal atrophy is on track to enroll all subjects by year-end 2004 and planned to be completed by first quarter 2005 -- Company approved for listing on American Stock Exchange: The Company`s common stock began trading on Amex(R) on September 23, 2004, under the symbol "AIS" -- Key management change and board additions: Mr. Jack E. Stover appointed to position of President, Chief Executive Officer and Director. Dr. Paul K. Wotton, President and CEO of Topigen Pharmaceuticals, Inc., appointed to Board of Directors -- European patent received for Easy Tec(TM) fast-melt technology
Total operating expenses for the three months ended September 30, 2004, totaled $2.6 million, as compared to $2.8 million for the same period in 2003. Research and development expenses increased 32% to $879,000. Total revenues for the quarter decreased to $613,000 from $1,040,000 in the same quarter in 2003. In the 2003 quarter, we experienced an increase in revenue as a major customer was preparing for the launch of our Medi-Jector VISION(R) device. Gross margin percentage increased in the third quarter of 2004 to 56.7% from 47.9% in the comparable quarter of 2003 due primarily to favorable results of outsourcing assembly operations.

At September 30, 2004, the Company had $11.1 million in cash, cash equivalents and short-term investments, compared to $1.9 million at December 31, 2003. The September 30, 2004, cash balance includes net proceeds of $15.1 million from the Company`s stock offering that closed in the first quarter of 2004.

Other income and expense decreased significantly from $21.0 million of expense to approximately $7,000 of income. Primarily this is attributable to the comparable 2003 quarter period containing non-cash debt conversion and extinguishment expenses of approximately $20.7 million.

Net loss per common share decreased from $1.40 per share to $0.06 per share due primarily to the absence of non-cash debt conversion and extinguishment charges in the current quarter, an increase in average common shares outstanding of 15,120,000 shares resulting from the $15.1 million stock offering, and reduced operating costs in the quarter as compared to the comparable quarter of 2003.

Commenting on the events of the third quarter, Jack E. Stover, President and Chief Executive Officer of Antares Pharma, said, "We are excited about the progress we are making as a specialty pharmaceutical company while managing our costs at a lower level in 2004 than 2003. Since coming on board in September, I continue to be pleased with the progress we are making, and I believe we are on the right track to deliver improved results on all fronts."

Year-to-Date Results

For the first nine months of the year, worldwide revenue decreased 29% to $2.03 million compared with revenue for the same period in 2003, due primarily to the 2003 launch of our Medi-Jector VISION(R) device by a major European customer. Gross margin as a percent of total revenue increased 6.5 percentage points from 43.6% to 50.1%. Operating expenses decreased approximately $475,000, or 6.5%, due primarily to decreases in payroll and investor relations expenses, partially offset by increases in R&D and sales and marketing expenses. Net loss per common share decreased from $2.23 per share to $0.17 per share due primarily to the absence of non-cash debt conversion and extinguishment charges in the current period and an increase in average common shares outstanding of 12,677,880 shares resulting from the $15.1 million stock offering in the first quarter 2004.

About Antares Pharma

Antares Pharma is a specialty pharma company focused on the growing lifestyle products sector and committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new products and devices. The Company`s current technology platforms include transdermal (Advanced Transdermal Delivery ATD(TM)) gels, disposable mini-needle injection systems (Vibex(TM)), reusable needle-free injection systems (VISION(R) and Valeo(TM)), and fast-melt oral (Easy Tec(TM)) tablets. The Company currently has active partnering programs with several pharmaceutical and distribution companies for a number of indications and applications, including diabetes, growth disorders, obesity, female sexual dysfunction and other hormone therapy.

Antares Pharma currently distributes its needle-free injector systems in more than 20 countries and markets the same technology for use with human growth hormone through licensees in most major regions of the world. Licensees also market an ibuprofen gel using Antares Pharma`s ATD(TM) technology in several major European countries. In addition, Antares Pharma is undertaking development or is conducting research on several product opportunities that will form the basis of its specialty pharma program. Antares Pharma`s corporate headquarters is in Exton, Pennsylvania, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company`s reports filed with the U.S. Securities and Exchange Commission. Antares Pharma claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

For more information, visit Antares Pharma`s web site at http://www.antarespharma.com. Information included on the Company`s website is not incorporated herein by reference or otherwise.

ANTARES PHARMA, INC. CONSOLIDATED BALANCE SHEETS (UNAUDITED) September 30, December 31, 2004 2003 Assets Current Assets: Cash and cash equivalents $1,135,402 $1,928,815 Short-term investments 9,964,935 -- Accounts receivable, net of allowances of $21,400 and $21,500, respectively 163,985 481,886 Other receivables 78,662 7,947 Inventories 159,038 225,408 Prepaid expenses and other assets 174,225 61,239 Total current assets 11,676,247 2,705,295 Equipment, furniture and fixtures, net 567,761 801,369 Patent rights, net 1,248,061 1,214,356 Goodwill 1,095,355 1,095,355 Other assets 345,455 138,478 Total Assets $14,932,879 $5,954,853 Liabilities and Shareholders` Equity Current Liabilities: Accounts payable $541,993 $253,336 Accrued expenses and other liabilities 622,649 827,676 Due to related parties 20,900 162,964 Capital lease obligations - current maturities 3,045 36,003 Deferred revenue - current 816,822 809,945 Total current liabilities 2,005,409 2,089,924 Deferred revenue - long term 3,024,166 3,557,835 Total liabilities 5,029,575 5,647,759 Shareholders` Equity: Series A Convertible Preferred Stock: $0.01 par; authorized 10,000 shares; 1,500 and 1,450 issued and outstanding at September 30, 2004 and December 31, 2003, respectively 15 15 Series D Convertible Preferred Stock: $0.01 par; authorized 245,000 shares; 63,588 and 243,749 issued and outstanding at September 30, 2004 and December 31, 2003, respectively 636 2,437 Common Stock: $0.01 par; authorized 100,000,000 shares; 39,913,406 and 19,831,296 issued and outstanding at September 30, 2004 and December 31, 2003, respectively 399,135 198,313 Additional paid-in capital 93,753,145 78,054,269 Accumulated deficit (80,002,246) (74,126,619) Prepaid license discount (2,747,490) (2,894,677) Deferred compensation (878,390) (306,808) Accumulated other comprehensive loss (621,501) (619,836) Total Shareholders` Equity 9,903,304 307,094 Total Liabilities and Shareholders` Equity $14,932,879 $5,954,853 ANTARES PHARMA, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) For the Three Months Ended For the Nine Months Ended September 30, September 30, 2004 2003 2004 2003 Revenue: Product sales $417,846 $692,830 $1,324,202 $2,068,387 Development revenue 35,706 115,028 180,668 165,328 Licensing fees 135,307 183,916 464,472 513,752 Royalties 24,316 48,185 61,034 110,920 Total revenue 613,175 1,039,959 2,030,376 2,858,387 Cost of sales: Cost of product sales 255,939 540,622 960,030 1,600,005 Cost of development revenue 9,734 1,271 53,926 13,445 Total cost of sales 265,673 541,893 1,013,956 1,613,450 Gross margin 347,502 498,066 1,016,420 1,244,937 Operating expenses: Research and development 879,297 666,210 2,147,260 2,068,325 Sales and marketing 216,469 137,677 450,802 340,586 General and administrative 1,477,672 2,026,421 4,180,110 4,844,016 2,573,438 2,830,308 6,778,172 7,252,927 Net operating loss (2,225,936) (2,332,242) (5,761,752) (6,007,990) Other income (expense): Loss on debt extinguishments -- -- -- (885,770) Loss on conversions of debt to equity -- (16,283,677) -- (16,283,677) Loss on common stock warrants -- (4,379,686) -- (5,960,453) Interest income 34,739 4,481 80,351 14,148 Interest expense (21,875) (356,834) (100,959) (894,139) Foreign exchange gains (losses) (2,727) 4,768 (13,467) (9,341) Other, net (3,386) (1,798) (8,371) (4,778) 6,751 (21,012,746) (42,446) (24,024,010) Net loss (2,219,185) (23,344,988) (5,804,198) (30,032,000) Preferred stock dividends -- -- (71,429) (50,000) Net loss applicable to common shares $(2,219,185) $(23,344,988) $(5,875,627) $(30,082,000) Basic and diluted net loss per common share $(0.06) $(1.40) $(0.17) $(2.23) Basic and diluted weighted average common shares outstanding 38,825,537 16,687,449 35,145,638 13,501,701
SOURCE Antares Pharma, Inc.

Jack E. Stover, President and CEO, [phone], or Lawrence M. Christian, CFO and Vice President - Finance, [phone], both of Antares Pharma; or Ira Weingarten or Steve Chizzik of Equity Communications, [phone] http://www.antarespharma.com

Copyright (C) 2004 PR Newswire. All rights reserved.

JS200

[js200]

11/15/2004 (16:54 ET) AIS: Q3 Results (6c) vs ($1.40); EPS +96% Y/Y; No Guidance - Knobias
11/15/2004 (16:22 ET) Antares Pharma, Inc. Reports Third Quarter 2004 Results - PR Newswire
11/15/2004 (14:21 ET) AIS: Filed New Form 10-Q, Quarterly Report - Knobias
11/10/2004 (14:21 ET) AIS: Volume Spike; 41% > 20-adsv, Stock EVEN - Knobias
11/10/2004 (12:32 ET) AIS: To Present At CIBC Healthcare Conf @ 15:30 ET - Knobias

[js200]

11/19/2004 (16:13 ET) AIS: Short Interest UP 4.1% to 413.7K in Nov 2004 - Knobias
11/19/2004 (15:10 ET) AIS: Volume Spike; 74% > 20-adsv, Stock +8.70% - Knobias
11/15/2004 (16:54 ET) AIS: Q3 Results (6c) vs ($1.40); EPS +96% Y/Y; No Guidance - Knobias
11/15/2004 (16:22 ET) Antares Pharma, Inc. Reports Third Quarter 2004 Results - PR Newswire
11/15/2004 (14:21 ET) AIS: Filed New Form 10-Q, Quarterly Report - Knobias

Last Trade: 1.490 Change: 0.110 (+7.971%)
Previous Close: 1.380 Volume: 771,400
Bid: N/A Ask: N/A
Today`s Open: 1.380 # of Trades: 152

JS200

[js200]

Positive Results From Study in Japan Using Antares Pharma`s Needle-Free Medi-Jector VISION(R) for the Delivery of Human Growth Hormone
via COMTEX

December 3, 2004

EXTON, Pa., Dec 3, 2004 /PRNewswire-FirstCall via COMTEX/ --

Antares Pharma, Inc. (Amex: AIS) announced today that Yutaka Igarashi, M.D., of the Igarashi Children`s Clinic in Miyagi, Japan, presented positive results at a symposium in Japan based on a long-term study conducted with Antares Pharma`s needle- free injection device, the Medi-Jector VISION(R), to deliver human growth hormone (hGH) to children with growth hormone deficiency.

Eighteen children used a needle-free device for four years, and growth results were compared against those of eight children who received hGH by conventional injection. There were no statistically significant differences in growth rates between the two groups. Most importantly, all of the children, each of whom had previously expressed concern about needle use, indicated a desire to continue using the Medi-Jector VISION(R) after the study was completed.

Dr. Igarashi`s study concluded, "There were no problems in safety, effectiveness [or] operation of the hGH treatment with [the Medi-Jector VISION(R)]. [The Medi-Jector VISION(R)] is an effective device for children who have aversion to needle injections, and it is useful for increasing options for hGH treatment."

Antares Pharma has licensed the Medi-Jector VISION(R) device to JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals announced in April 2004 that the device had been approved in Japan for the administration of hGH and began marketing this generation of the device in Japan in August 2004 under the brand name Twin-Jector(R) EZ II.

According to estimates based on Japan National Health Insurance information, the Japanese hGH market is an important worldwide market for hGH, estimated at approximately $500 million annually. Pfizer, Novo Nordisk, Eli Lilly and Company, Serono and JCR Pharmaceuticals offer hGH products to the Japanese market. A company representative from JCR Pharmaceuticals stated, "We believe the introduction of Antares Pharma`s needle-free device coupled with our human growth hormone product strengthens our competitive position in this marketplace. We are pleased to offer this patient-friendly product to our customers."

Commenting on the study results, Jack E. Stover, President and Chief Executive Officer of Antares Pharma, said, "The results from Dr. Igarashi`s study help support the awareness that our VISION(R) needle-free delivery system replicates the delivery of drugs currently given with needle-based devices. We believe that the VISION(R) needle-free system for hGH and other drugs encourages improved patient compliance while helping to achieve better medical outcomes. In 2003, Greystone Associates projected that the needle- free injection market for hGH patients that are self-administered will grow to more than 30% of the market by 2007 from less than 3% of the market in 2002. We look forward to working closely with JCR Pharmaceuticals as it introduces this exciting product into the Japan marketplace."

About Antares Pharma

Antares Pharma is a specialty pharma company focused on the growing lifestyle products sector and committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new products and devices. The Company`s current technology platforms include transdermal (Advanced Transdermal Delivery ATD(TM)) gels, disposable mini-needle injection systems (Vibex(TM)), reusable needle-free injection systems (VISION(R) and Valeo(TM)), and fast-melt oral (Easy Tec(TM)) tablets. The Company currently has active partnering programs with several pharmaceutical and distribution companies for a number of indications and applications, including diabetes, growth disorders, obesity, female sexual dysfunction and other hormone therapy.

Antares Pharma currently distributes its needle-free injector systems in more than 20 countries and markets the same technology for use with human growth hormone through licensees in most major regions of the world. Licensees also market an ibuprofen gel using Antares Pharma`s ATD(TM) technology in several major European countries. In addition, Antares Pharma is undertaking development or is conducting research on several product opportunities that will form the basis of its specialty pharma program. Antares Pharma`s corporate headquarters is in Exton, Pennsylvania, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company`s reports filed with the U.S. Securities and Exchange Commission. Antares Pharma claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

For more information, visit Antares Pharma`s web site at http://www.antarespharma.com. Information included on the Company`s website is not incorporated herein by reference or otherwise.

SOURCE Antares Pharma, Inc.

Jack E. Stover, President and CEO, or Lawrence M. Christian, CFO and Vice President - Finance, both of Antares Pharma, [phone]; or Steve Chizzik/Ira Weingarten of Equity Communications, [phone], for Antares Pharma http://www.antarespharma.com

Copyright (C) 2004 PR Newswire. All rights reserved.


JS200

[js200]

12/03/2004 (09:18 ET) AIS: Presents Positive Data re Needle-Free Injection Device - Knobias
12/03/2004 (09:01 ET) Positive Results From Study in Japan Using Antares Pharma`s Needle-Free Medi-Jector VISION(R) for the Delivery of Human Growth Hormone - PR Newswire
11/19/2004 (16:13 ET) AIS: Short Interest UP 4.1% to 413.7K in Nov 2004 - Knobias
11/19/2004 (15:10 ET) AIS: Volume Spike; 74% > 20-adsv, Stock +8.70% - Knobias
11/15/2004 (16:54 ET) AIS: Q3 Results (6c) vs ($1.40); EPS +96% Y/Y; No Guidance - Knobias

[js200]

Antares Pharma Hires Key Business Development Executive
via COMTEX

February 15, 2005

EXTON, Pa., Feb 15, 2005 /PRNewswire-FirstCall via COMTEX/ --

Antares Pharma, Inc. (Amex: AIS) today announced that it has hired James E. Hattersley, an accomplished business development professional, as its Vice President of Corporate Business Development. Mr. Hattersley will be a key member of Antares Pharma`s management team, focusing, along with Jack Stover, on building strategic relationships with new pharmaceutical partners while broadening and expanding key existing relationships.

Prior to joining Antares Pharma, Mr. Hattersley served as Senior Director of Business Development at Eurand, Inc., a global drug delivery and specialty pharma company. While there, he was responsible for identifying partners and executing a series of development and commercial license agreements that helped contribute to Eurand`s exceptional top-line growth during the past five-year period.

Mr. Hattersley said he was attracted to Antares Pharma because of its three core drug development platforms, which he characterized as "an impressive technology base." Given this base, Mr. Hattersley stated, "Antares has a large number of potential projects, each of which appears to be attractive to one or more strategic partners." He went on to say, "Given the current objectives of big pharma in the drug delivery area, I believe the timing for Antares is attractive, especially as it relates to strategic partnership opportunities."

Mr. Stover and Mr. Hattersley said, "As we examine Antares` current pipeline and portfolio, we believe that by retaining greater ownership in our projects and also developing some products under our own brand name, Antares can position itself to be a more significant specialty pharmaceutical player." Mr. Stover added, "The addition of Jim provides the leadership skills, including strong industry relationships and expertise, to help Antares move rapidly to leverage its pharmaceutical-based technologies and expand its commercial opportunities."

Before Eurand, Mr. Hattersley was employed by Anesta Corp., where he was responsible for developing corporate strategy and for identifying product licensing partners in the Asia Pacific region. From 1995 to 1998, Mr. Hattersley was employed by Swiss-based JAGO Pharma AG as Director of Program Management, managing its partnerships in North America. Mr. Hattersley has also held technical positions at Abbott Laboratories, Syntex Research USA and Alza Corporation between 1986 and 1995. Mr. Hattersley received an M.S. degree in biochemistry in 1986 and an undergraduate degree in neurobiology in 1985, both from the University of California.

About Antares Pharma

Antares Pharma is a specialty pharma company focused on the growing lifestyle products sector and committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new products and devices. The Company`s current technology platforms include transdermal (Advanced Transdermal Delivery ATD(TM)) gels, disposable mini-needle injection systems (Vibex(TM)), reusable needle-free injection systems (VISION(R) and Valeo(TM)), and fast-melt oral (Easy Tec(TM)) tablets. The Company currently has active partnering programs with several pharmaceutical and distribution companies for a number of indications and applications, including diabetes, growth disorders, obesity, female sexual dysfunction and other hormone therapy.

Antares Pharma currently distributes its needle-free injector systems in more than 20 countries and markets the same technology for use with human growth hormone through licensees in most major regions of the world. Licensees also market an ibuprofen gel using Antares Pharma`s ATD(TM) technology in several major European countries. In addition, Antares Pharma is undertaking development or is conducting research on several product opportunities that will form the basis of its specialty pharma program. Antares Pharma`s corporate headquarters is in Exton, Pennsylvania, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company`s reports filed with the U.S. Securities and Exchange Commission. Antares Pharma claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

For more information, visit Antares Pharma`s web site at http://www.antarespharma.com and its needle-free product website, http://www.mediject.com. Information included on the Company`s website is not incorporated herein by reference or otherwise.

SOURCE Antares Pharma, Inc.

Jack E. Stover, President and CEO, [phone], or Lawrence M. Christian, CFO an Vice President - Finance, [phone], both of Antares Pharma, or Steve Chizzik or Ira Weingarten of Equity Communications, [phone], for Antares Pharma http://www.prnewswire.com

Copyright (C) 2005 PR Newswire. All rights reserved.

Print story

Current Quote

AMX: AIS
Finance/Real Estate

Last: 1.340
Change: N/A
Volume: N/A
Day High: N/A
Day Low: N/A


JS200

[js200]

Antares Pharma Receives GMP Approval of Swiss Facility; An Important Milestone in the Specialty Pharma Strategy
via COMTEX

March 10, 2005

EXTON, Pa., March 10, 2005 /PRNewswire-FirstCall via COMTEX/ --

Antares Pharma Inc. (Amex: AIS) a specialty pharmaceutical company that develops and licenses drug delivery technology for next generation lifestyle products, announced today that its Swiss subsidiary, Antares Pharma AG, located in Allschwil BL, Switzerland, has received approval from the Swiss Medic (Swiss Medical Institute) to produce and wholesale semisolid dosage forms specifically related to its Advanced Transdermal Delivery (ATD(TM)) gels for:

-- Producing intermediate products and end-user medicaments -- Producing for clinical trials -- Packaging for clinical trials -- Primary and secondary packaging -- Chemical, physical and biochemical quality assurance as an external laboratory

Commenting on the achievement, Dr. Dario Carrara, Managing Director for Antares Pharma`s European operations, said, "We are delighted with the GMP approval of our Swiss facility. This accomplishment will allow us to accelerate the development of our proprietary ATD(TM) gel technology and expand our proprietary product offerings. This approval also classifies our facility, procedures and staff as ready to take on more significant growth opportunities in a cost effective way."

Jack E. Stover, President and CEO of Antares Pharma, said, "Dr. Carrara and his team have accomplished an important milestone in our specialty pharmaceutical development strategy. We believe this accomplishment will help accelerate all of our plans to develop and commercialize our gel-based products."

About Antares Pharma

Antares Pharma is a specialty pharma company focused on the growing lifestyle products sector and committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new products and devices. The Company`s current technology platforms include transdermal (Advanced Transdermal Delivery ATD(TM)) gels, disposable mini-needle injection systems (Vibex(TM)), reusable needle-free injection systems (VISION(R) and Valeo(TM)), and fast-melt oral (Easy Tec(TM)) tablets. The Company currently has active partnering programs with several pharmaceutical and distribution companies for a number of indications and applications, including diabetes, growth disorders, obesity, female sexual dysfunction and other hormone therapy.

Antares Pharma currently distributes its needle-free injector systems in many countries and markets the same technology for use with human growth hormone through licensees in most major regions of the world. Licensees also market an ibuprofen gel using Antares Pharma`s ATD(TM) technology in several major European countries. In addition, Antares Pharma is undertaking development or is conducting research on several product opportunities that will form the basis of its specialty pharma program. Antares Pharma`s corporate headquarters is in Exton, Pennsylvania, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company`s reports filed with the U.S. Securities and Exchange Commission. Antares Pharma claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

For more information, visit Antares Pharma`s web site at http://www.antarespharma.com and its needle-free product website, http://www.mediject.com. Information included on the Company`s website is not incorporated herein by reference or otherwise.

SOURCE Antares Pharma Inc.

Jack E. Stover, President and CEO, or Lawrence M. Christian, CFO and Vice President Finance, both of Antares Pharma, [phone]; or Steve Chizzik http://www.prnewswire.com

Copyright (C) 2005 PR Newswire. All rights reserved.

[js200]

03/18/2005 (13:24 ET) MARKET: Indices Fall Mid-Day; SI Buys CTMI - Knobias
03/18/2005 (11:12 ET) AIS: Q4 Results (6c) vs (15c); EPS +60% Y/Y; No Guidance - Knobias
03/18/2005 (11:10 ET) Antares Pharma, Inc. Reports Fourth Quarter and 2004 Results and Progress - PR Newswire
03/18/2005 (09:12 ET) AIS: Filed New Form DEF 14A, Definitive Proxy Statement - Edgar
03/17/2005 (16:27 ET) AIS: Filed New Form 10-K, Annual Report - Edgar

[Hufeland]

aber der kurs ist unbeeindruckt, seit monaten leicht abwärts seitwärts.

Wann zündet die Rakete?

Hufeland

[js200]

Antares Pharma`s Licensee Announces Transdermal Estradiol Gel (Bio-E-Gel(TM)) Significantly Reduces Number and Severity of Hot Flashes in Menopausal Women
via COMTEX

July 7, 2005

- No Significant Difference in Safety Profile Compared to Placebo
- Phase III Trial Results Indicate Lowest Effective Dose for Estrogen Therapy

EXTON, Pa., July 7, 2005 /PRNewswire-FirstCall via COMTEX/ --

Antares Pharma, Inc. (Amex: AIS), a specialized pharmaceutical product development company with patented drug delivery systems and injectable device engineering capabilities, announced today that its North American licensee, BioSante Pharmaceuticals, Inc., has announced significant Phase III safety and efficacy results of bioidentical estradiol transdermal gel (Bio-E-Gel(TM)) for the treatment of moderate-to-severe hot flashes in menopausal women. A new drug application (NDA) is expected to be filed as soon as possible after completion of the data analysis, which is projected to be around the end of September.

Bio-E-Gel(TM) utilizes Antares Pharma`s proprietary Advanced Transdermal Delivery (ATD(TM)) gel system, which is designed to allow delivery of hormones and other active ingredients across the skin. Antares Pharma`s ATD(TM) gel system also allows active ingredients to be quickly absorbed through the skin following application to the arms, shoulders or abdomen, evenly delivering pharmaceuticals to the bloodstream in a non-invasive and painless manner. Estrogen products are currently approved for the treatment of menopausal symptoms, including hot flashes and vaginal atrophy. The current U.S. market for estrogen products is estimated at approximately $1.4 billion in annual sales, and the European market for estrogen products is estimated to be equally substantial to the U.S. market.

While Antares Pharma has licensed its estradiol gel in its patented ATD(TM) system to BioSante for North America and certain other territories, Antares Pharma retains all rights to utilize and reference the data obtained from clinical trials in order to develop, market and license its own estradiol ATD(TM) gel products in Europe, Japan and other important markets. Additionally, Antares Pharma expects to receive contractually agreed milestone payments at certain stages of development and royalties on end sales in North America upon commercialization.

According to BioSante, its Phase III trial was a 12-week, randomized, double-blind, placebo-controlled study of 484 symptomatic menopausal women. Following FDA recommendations, the Phase III trial tested three doses in order to establish the lowest effective dose and maximize the safety profile. For all doses tested, there was a clear dose response in the reduction in the number and severity of hot flashes. In addition, there was no significant difference in the safety profile of any dose compared to placebo. A full report of the Phase III trial data is expected to be issued at a medical meeting this coming fall, followed by publication in a peer-reviewed journal.

Jack E. Stover, President and CEO of Antares Pharma, said, "We are very pleased with the Phase III study results announced because it appears BioSante has not only demonstrated statistically significant efficacy at all three doses studied - low, medium, and high - but also may have identified the lowest effective dose of estrogen therapy. This could prove a key competitive advantage in the current environment of heightened sensitivity to drug safety, particularly for hormone therapies. Antares Pharma is now developing its own plans for regulatory submission and commercialization of its estradiol ATD(TM) gel in Europe, Japan and other markets."

About Antares Pharma

Antares Pharma is a specialized pharma product development company with patented drug delivery systems and injectable device engineering capabilities. The Company`s current technology platforms include its ATD(TM) (Advanced Transdermal Delivery) system, Easy Tec(TM) oral fast-melt technology, and subcutaneous injection technology platforms (Vibex(TM) disposable mini-needle injection device and Valeo(TM) and Vision(R) reusable needle-free injection devices). Antares Pharma is committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new products and devices. The Company believes its product pipeline addresses unmet medical needs by reducing side effect profiles, improving safety, increasing effectiveness, and improving patient compliance and convenience.

The Company has active partnering programs with several pharmaceutical and distribution companies for a number of indications and applications, including diabetes, growth disorders, obesity, female sexual dysfunction and other hormone therapy. Its needle-free injector system is distributed in more than 30 countries for the administration of insulin and is marketed for use with human growth hormone through licensees in most major regions of the world. Licensees also market an ibuprofen gel using Antares Pharma`s ATD(TM) technology in several major European countries. In addition, Antares Pharma is undertaking development or is conducting research on several product opportunities that it expects will form the basis of its specialized pharma program.

Antares Pharma has corporate headquarters in Exton, Pennsylvania, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company`s reports filed with the U.S. Securities and Exchange Commission. Antares Pharma claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

For more information, visit Antares Pharma`s web site at http://www.antarespharma.com and its needle-free product website, http://www.mediject.com. Information included on the Company`s websites is not incorporated herein by reference or otherwise.

SOURCE Antares Pharma, Inc.

Jack E. Stover, President and CEO, [phone], or Lawrence M. Christian, CFO an Vice President - Finance, [phone], both of Antares Pharma; or Steve Chizzik or Ira Weingarten of Equity Communications, [phone], for Antares Pharma http://www.prnewswire.com

Copyright (C) 2005 PR Newswire. All rights reserved.

[js200]

Antares Pharma Announces Conversion of All Outstanding Shares of Series A Convertible Preferred Stock
via COMTEX

July 11, 2005

EXTON, Pa., July 11, 2005 /PRNewswire-FirstCall via COMTEX/ --

Antares Pharma, Inc. (Amex: AIS), a specialized pharmaceutical product development company with patented drug delivery systems and injectable device engineering capabilities, today announced that Elan Pharmaceutical Investments, Ltd. (Elan) has converted 1,500 shares of Antares` Series A Convertible Preferred Stock (representing all outstanding shares of Series A Convertible Preferred Stock) into 1.2 million shares of common stock at a conversion price of $1.25 per share, and that Elan has also agreed to certain lock-up provisions regarding the disposal of the newly issued shares. Other terms of the agreement were not disclosed.

Commenting on this conversion, Lawrence M. Christian, Vice President- Finance and CFO of Antares Pharma, said, "The conversion eliminates all outstanding shares of Antares` Series A Convertible Preferred Stock leaving only approximately 33,000 Series D preferred shares outstanding. This provides a more straightforward capital structure for our future growth."

About Antares Pharma

Antares Pharma is a specialized pharma product development company with patented drug delivery systems and injectable device engineering capabilities. The Company`s current technology platforms include its ATD(TM) (Advanced Transdermal Delivery) system, Easy Tec(TM) oral fast-melt technology, and subcutaneous injection technology platforms (Vibex(TM) disposable mini-needle injection device and Valeo(TM) and Vision(R) reusable needle-free injection devices). Antares Pharma is committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new products and devices. The Company believes its product pipeline addresses unmet medical needs by reducing side effect profiles, improving safety, increasing effectiveness, and improving patient compliance and convenience.

The Company has active partnering programs with several pharmaceutical and distribution companies for a number of indications and applications, including diabetes, growth disorders, obesity, female sexual dysfunction and other hormone therapy. Its needle-free injector system is distributed in more than 30 countries for the administration of insulin and is marketed for use with human growth hormone through licensees in most major regions of the world. Licensees also market an ibuprofen gel using Antares Pharma`s ATD(TM) technology in several major European countries. In addition, Antares Pharma is undertaking development or is conducting research on several product opportunities that it expects will form the basis of its specialized pharma program.

Antares Pharma has corporate headquarters in Exton, Pennsylvania, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company`s reports filed with the U.S. Securities and Exchange Commission. Antares Pharma claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

For more information, visit Antares Pharma`s web site at http://www.antarespharma.com and its needle-free product website, http://www.mediject.com. Information included on the Company`s websites is not incorporated herein by reference or otherwise.

SOURCE Antares Pharma, Inc.

Jack E. Stover, President and CEO, [phone] or Lawrence M. Christian, CFO and Vice President - Finance, [phone], both of Antares Pharma, or Steve Chizzik or Ira Weingarten, Equity Communications, [phone] http://www.prnewswire.com

Copyright (C) 2005 PR Newswire. All rights reserved.